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Abstract: INTRODUCTION: We hypothesized that common Alzheimer's disease 
(AD)-associated variants within the triggering receptor expressed on 
myeloid (TREM) gene cluster influence disease through gene expression. 
METHODS: Expression microarrays on temporal cortex and cerebellum from 
~400 neuropathologically diagnosed AD and non-AD subjects, and two 
independent RNAseq replication cohorts were used for expression 
quantitative trait locus (eQTL) analysis. 
RESULTS: TREML1 and TREM2 have reliably detectable expression. A variant 
within a DNase hypersensitive site 5' of TREM2, rs9357347-C, associates 
with reduced AD-risk and increased TREML1 and TREM2 levels. Meta-analysis 
on eQTL results from three independent datasets (n=1,006) confirmed these 
associations (p=3.4x10-2 and 3.5x10-3, respectively). 
DISCUSSION: Our findings point to rs9357347 as a functional regulatory 
variant that contributes to a protective effect observed at the TREM 
locus in the International Genomics of Alzheimer's Project (IGAP) GWAS 
meta-analysis, and suggest concomitant increase of TREML1 and TREM2 brain 
levels as a potential mechanism for protection from AD.  
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August 18, 2016 
 
 
To: Zaven Khachaturian, PhD, Editor-in-Chief, Alzheimer's & Dementia: The Journal of the 
Alzheimer's Association 
 
 
Dear Dr. Khachaturian: 
 
This is a re-submission of our manuscript “A candidate regulatory variant at the TREM gene 
cluster associates with decreased Alzheimer’s disease risk, and increased TREML1 and TREM2 
brain gene expression” (ADJ-D-16-00130) to Alzheimer's & Dementia: The Journal of the 
Alzheimer's Association for consideration as an original research article. The re-submission is an 
extensively revised version of our manuscript, which was modified to address each of the 
comments by all four of our Reviewers. 
 
We are extremely grateful for the thoughtful and thorough reviews of our manuscript. We were 
delighted to receive the many positive comments, which included the following: “This work is 
significant both for the TREM locus and potentially as a more general approach for other AD-
risk loci.  Strengths of the study include the strong replication/validation strategy and the focus 
on identification and characterization of functional regulatory genetic variants” (Reviewers); 
“The paper has an interesting finding… This study was based on well characterized IGAP and 
Mayo Clinic cohorts with adequate study sizes.” (Reviewer 1); “The expression association 
analysis was well designed and thoroughly executed. The study includes appropriate replication 
cohorts.  The study contributes to the understanding of the broader role of TREM locus in AD, 
beyond the rare coding mutations; the results are of interest to the community of investigators 
studying the genetic of LOAD.” (Reviewer 2); “Overall, the paper is well written. Methodology 
and results are well structured. The identification of several putative eQTL variants and 
selection of the putative causal variant are described in detail.” (Reviewer 4); “Overall nicely 
done analyses, just a couple comments” (Reviewer 5).    
Carrasquillo_etal_TREM_CoverLetter_08-18-2016
 
We believe that we have addressed each of the comments of all of the Reviewers and that the 
changes we made in response to each of the comments have further strengthened our manuscript. 
Our revision consisted of addressing 29 main and 11 minor comments. Our responses are 
detailed in our 29-page point-by-point responses to the comments document submitted with this 
revision. Our revised manuscript and supplementary material includes modifications made to 2 
Main and 1 Supplementary Tables; addition of 4 new Supplementary Tables and 2 new 
Supplementary Figures and inclusion of text to satisfactorily address all comments. Our revised 
manuscript continues to show the association of a variant in a regulatory region of the TREM 
locus with elevated brain TREML1 and TREM2 gene expression in 1,006 brains and decreased 
Alzheimer’s disease (AD) risk. This variant may explain the AD risk association observed at the 
TREM locus in the IGAP AD-risk GWAS meta-analysis. Our findings suggest that common, 
regulatory TREM locus variants could influence risk for late-onset AD, in addition to the rare, 
coding TREM2 variants previously shown to confer LOAD risk (1). Below, we provide 
additional details about our work:           
 
In 2013, our group contributed to the discovery of a rare missense variant (p.R47H) in the 
TREM2 gene that has since been established as a strong genetic risk factor for LOAD (1). 
TREM2 is a member of the triggering receptor expressed on myeloid (TREM) family that is 
located within a TREM gene cluster on chromosome 6p21.1, which includes the coding genes 
TREM1, TREML1, TREML2 and TREML4. These genes could be plausible AD risk genes in 
addition to TREM2. There have been several reports of associations between a common TREM2 
intergenic variant (2), TREML2 coding variant (3) and a TREM1 variant (4) with risk for AD or 
its quantitative endophenotypes. These common variants appear to have effects that are 
independent from that of the initially reported rare TREM2 coding variant. 
 
In this manuscript, we sought to evaluate the effect of common AD-risk variants at the TREM 
locus on TREM family genes by a combined disease risk and gene expression association 
approach. We hypothesize that some of the common AD-risk variants at the TREM locus confer 
disease risk via regulation of transcript levels of some of the coding genes at the TREM gene 
cluster. Based on this hypothesis, we expect to identify common AD-risk variants at the TREM 
locus and distinguish the TREM family gene that they influence by their effects on gene 
expression levels.  
 
In this study, we first characterized the brain expression levels of the TREM family genes using 
microarray expression data in a large cohort of ~400 neuropathologically diagnosed AD and 
non-AD subjects, validated the results by next-generation RNA sequencing (RNAseq), and 
determined that of the TREM locus genes, only TREM2 and TREML1 are expressed above 
background in the brain regions that were evaluated. We subsequently tested the association of 
TREM2 and TREML1 expression levels with single nucleotide polymorphisms (SNP) that were 
also tested in the IGAP AD-risk GWAS meta-analysis, and annotated these variants for their 
effects on AD risk, TREM gene expression levels and regulatory potential. We identified a 
variant with strong regulatory potential, rs9357347 located upstream of TREM2, which is 
associated with both reduced AD-risk and with increased levels of TREML1 and TREM2 in the 
temporal cortex. This variant is in strong linkage disequilibrium with the intergenic variant that 
drives the AD-risk association observed in the IGAP meta-analysis at the TREM locus.  
 
To validate our findings we obtained data from two additional cohorts with brain RNA 
sequencing data (a second cohort from Mayo Clinic and the ROS/MAP cohort from Rush 
University), thereby increasing our sample size from 380 brains to 1,006 brains. The meta-
analyses of these cohorts revealed increased significance for the TREM2 level association with 
rs9357347 (p=3.54x10-3) and continued association with TREML1 levels (p=3.36x10-2).   
 
We have also performed a detailed annotation of the variants at the TREM locus and determined 
that rs9357347 resides within sequence subject to histone modifications and within a DNase 
hypersensitive site detected by the Roadmap Epigenomics Consortium in brain regions relevant 
to AD pathology such as the hippocampus. Furthermore, it is predicted to affect relevant 
transcription factor binding as catalogued in HaploReg. 
 
Our study currently represents one of the largest investigations of TREM locus variants for their 
role on brain expression of genes at this site, identifies a variant with strong regulatory potential, 
association with brain TREM2 and TREML1 expression in our original cohort and meta-analysis 
of 1,006 brains, and also AD risk association. Our findings suggest that transcriptional regulation 
at this site may be an important and novel mechanism in modulating AD risk and provides a 
testable hypothesis regarding a specific variant and transcription factors. 
 
We hope that you may find our manuscript meritorious of publication in your journal. We look 
forward to your response. 
 
Sincerely, 
 
 
 
Nilüfer Ertekin-Taner, MD, PhD 
Associate Professor of Neurology 
Associate Professor of Neuroscience  
Departments of Neuroscience and Neurology 
Mayo Clinic Jacksonville, FL 32224 
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Abstract  30 
 31 
INTRODUCTION: We hypothesized that common Alzheimer’s disease (AD)-associated 32 
variants within the triggering receptor expressed on myeloid (TREM) gene cluster influence 33 
disease through gene expression. 34 
METHODS: Expression microarrays on temporal cortex and cerebellum from ~400 35 
neuropathologically diagnosed AD and non-AD subjects, and two independent RNAseq 36 
replication cohorts were used for expression quantitative trait locus (eQTL) analysis. 37 
RESULTS: TREML1 and TREM2 have reliably detectable expression. A variant within a DNase 38 
hypersensitive site 5’ of TREM2, rs9357347-C, associates with reduced AD-risk and increased 39 
TREML1 and TREM2 levels. Meta-analysis on eQTL results from three independent datasets 40 
(n=1,006) confirmed these associations (p=3.4x10
-2
 and 3.5x10
-3
, respectively). 41 
DISCUSSION: Our findings point to rs9357347 as a functional regulatory variant that 42 
contributes to a protective effect observed at the TREM locus in the International Genomics of 43 
Alzheimer’s Project (IGAP) GWAS meta-analysis, and suggest concomitant increase of 44 
TREML1 and TREM2 brain levels as a potential mechanism for protection from AD.  45 
 46 
 47 
 48 
Keywords: Alzheimer's disease, eQTL, TREM2, TREML1, regulatory variant  49 
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1. Introduction 50 
Whole genome and exome sequencing are used as complementary approaches to uncover 51 
novel loci that can be missed by GWAS, and enabled the discovery of rare, missense alleles 52 
within TREM2 that have a relatively large effect size on AD-risk  [1, 2]. TREM2 is a member of 53 
the triggering receptor expressed on myeloid (TREM) family, known to play a key role in 54 
modulating inflammation in the innate immune response [3]. This finding provided strong 55 
supportive evidence for the importance of inflammation in the etiology of AD, but the specific 56 
role played by TREM2 in AD pathophysiology remains unclear [4].   57 
Since the first two reports [1, 2], the risk effect of the most significant TREM2 rare 58 
missense variant p.R47H (a.k.a. rs75932628) has been replicated in multiple Caucasian series [5-59 
9], including a large meta-analysis of 24,086 AD cases and 148,993 controls [10]. TREM2 60 
resides within the TREM gene cluster on chromosome 6p21.1 (Fig. 1), which also includes the 61 
protein coding genes TREM1, TREML1, TREML2, TREML4 that could be additional plausible 62 
AD-risk genes. 63 
A missense variant in TREML2, p.S144G (a.k.a. rs3747742), that is not in linkage 64 
disequilibrium (LD) with TREM2 p.R47H, was reported to associate with reduced AD-risk [11]. 65 
TREML2 p.S144G is in tight LD with the intergenic variant, rs9381040, that demonstrated the 66 
most significant association at the TREM locus in the IGAP AD-risk GWAS meta-analysis 67 
(p=6x10
-04
) [12]. The authors concluded that TREML2 p.S144G is the functional variant that 68 
accounted for the IGAP TREM locus signal, even though the significance of the AD-risk 69 
association with the intergenic rs9381040 is greater than that observed with p.S144G. Further, 70 
TREML2 p.S144G does not have a predicted functional consequence (PolyPhen2 score=benign) 71 
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or demonstrated functional outcome, suggesting that the IGAP signal at the TREM locus may be 72 
due to other functional variants.  73 
Some variants at the TREM locus have been reported to show association with AD 74 
endophenotypes [11, 13, 14]. Cerebrospinal fluid (CSF) levels of AD biomarkers, tau and ptau, 75 
associate with three variants at the TREM locus that are not in LD with each other: TREM2 76 
p.R47H (rs75932628), rs6916710 located in intron 2 of TREML2, and rs6922617 located 77 
downstream from NCR2 and outside the TREM cluster. Of these variants, only TREM2 p.R47H 78 
was associated with AD-risk [13]. More recently, a variant upstream of TREM2 (rs7759295) and 79 
a variant in intron 3 of TREM1 (rs6910730) were reported to be independently associated with 80 
increased AD pathology burden and increased rate of cognitive decline [14]. However, neither of 81 
these two variants shows association with AD-risk in the IGAP meta-analysis (p>0.05) [15]. 82 
Thus, other than TREM2 p.R47H, none of the TREM locus variants previously reported to 83 
associate with AD endophenotypes show association with AD-risk. Functional AD-risk variants 84 
that influence AD endophenotypes are expected to show association both with these 85 
endophenotypes and risk of AD. Therefore, it is possible that these latter variants are not the 86 
functional variants per se, but merely markers of other un-tested functional variants.  87 
Collectively, these prior findings suggest that besides the TREM2 rare missense variants, 88 
there may be common variants at the TREM locus that influence AD-risk and/or its 89 
endophenotypes. We hypothesized that some of the common AD-risk variants at the TREM locus 90 
confer disease risk via regulation of transcript levels of coding genes at the TREM gene cluster. 91 
In this study, we characterized the brain expression levels of the TREM family genes using 92 
microarray expression data; validated expression levels by RNA sequencing (RNAseq); 93 
performed genetic associations with TREM locus genes reliably detected in cerebellum and 94 
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temporal cortex with single nucleotide polymorphisms (SNP) that were also tested in the IGAP 95 
AD-risk GWAS meta-analysis; and annotated these variants for their effects on TREM gene 96 
expression levels and regulatory potential. Further, we obtained results for the top putative 97 
regulatory SNP from two other, independent cohorts with brain RNAseq data and performed 98 
meta-analysis of all three cohorts.  99 
 100 
2. Materials and Methods 101 
2.1 Variant selection 102 
We restricted our analysis to variants located within 100kb of any coding TREM family 103 
gene at the chromosome 6p21.1 TREM gene cluster (Fig. 1). Variants were further selected 104 
based on the statistical significance of their AD-risk association in the IGAP stage 1 meta-105 
analysis [12] (Supplementary Methods), where only those variants with p-values  0.0015 were 106 
kept. This p-value cut-off was arbitrarily chosen to select those variants that existed in both the 107 
IGAP stage 1 AD GWAS and our discovery eQTL cohort, Mayo Clinic Whole Genome-DASL 108 
dataset, and that could be genotyped, if needed, in the replication eQTL cohorts, using cost-109 
effective medium-throughput assays. Variants were further prioritized by their Regulome score. 110 
Regulome scores were obtained from the Regulome database, which annotates variants with 111 
regulatory information from 962 different datasets and a variety of sources, including ENCODE 112 
[16]. Regulome scores are on a scale from 1 to 6, and these numerical categories are sub-113 
classified with letters based on the number of lines of evidence of functional consequence. A 114 
value of 1a is assigned to the variant with the most evidence of regulatory potential, while a 115 
score of 6 has the least [16]. 116 
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2.2 Mayo Clinic Whole Genome-DASL dataset (Discovery eQTL cohort) 117 
We utilized Illumina (Whole Genome-DASL=WG-DASL, Illumina, San Diego, CA) 118 
microarray gene expression data from our published human brain expression genome-wide 119 
association study (Mayo Clinic eGWAS) [17] conducted on brain tissue from autopsied AD 120 
patients (197 cerebellum, 202 temporal cortex) and non-AD subjects (177 cerebellum, 197 121 
temporal cortex) (Table 1). All AD subjects had neuropathologic diagnosis of definite AD [2]. 122 
The non-AD subjects did not fulfill neuropathologic criteria for definite AD, but many had other 123 
unrelated pathologies. Expression measures were generated as described previously [17]. A 124 
description of this cohort and generation of expression measures is provided in the 125 
Supplemetary Methods.  126 
2.3 RNAseq datasets (Replication eQTL cohorts) 127 
Temporal cortex RNAseq data from two RNAseq cohorts: “Mayo Clinic RNASeq” and 128 
“ROS/MAP RNAseq” were employed for replication of the associations that were detected with 129 
the WG-DASL gene expression measurements. The Mayo Clinic RNASeq dataset is comprised 130 
of 84 LOAD and 48 non-AD brains from the Mayo Clinic Brain Bank that were not part of the 131 
Mayo Clinic WG-DASL cohort but whose neuropathological diagnosis followed the same 132 
criteria. The ROS/MAP RNAseq dataset is comprised of RNAseq data from 288 AD and 206 133 
non-AD samples that are part of the ROS/MAP cohort (Table 1) previously described [18, 19]. 134 
Methodological details for the RNAseq data generation are provided in the Supplementary 135 
Methods. 136 
2.4. Statistical Analysis 137 
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Normalized transcript expression levels, on a log2 scale, were tested for associations with 138 
TREM locus genotypes in each of the three datasets (Mayo WG-DASL, Mayo Clinic RNAseq 139 
and ROS/MAP RNAseq) via multivariable linear regression analyses implemented in PLINK 140 
[20]. An additive model was applied adjusting for age-at-death, sex, diagnosis, RNA Integrity 141 
Number (RIN) and adjusted RIN squared (RIN-RINmean)
2
 in all expression analyses, and APOE 142 
4 dosage and PCR plate in Mayo WG-DASL only, and flowcell in the Mayo Clinic RNAseq 143 
dataset only. The eQTL analysis in the discovery, WG-DASL dataset, included APOE 4 dose as 144 
a covariate given the strong effect of this allele on AD. However, since a significant association 145 
was not detected with this covariate in the rs9357347 eQTL analyses in the discovery set, APOE 146 
4 dose was not included in the eQTL analyses implemented on the replication cohorts. For 147 
comparison, we have performed the eQTL analyses in all three datasets with and without 148 
adjustment for APOE 4 dose and do not observe a substantial difference in the association 149 
results between these two models. 150 
Meta-analyses were performed on eQTL results from the three independent datasets. For 151 
these analyses, METAL [21] was implemented using weighted average of z-scores from the 152 
individual study p-values, weighted according their sample size. 153 
 154 
3. Results 155 
In the WG-DASL gene expression data from the temporal cortex (n=399) and cerebellum 156 
(n=374) of neuropathologically diagnosed AD and non-AD subjects (Table 1), we observed that 157 
of the 5 TREM locus coding genes, only TREML1 and TREM2 were reliably detected (Table S1 158 
and Fig. 2). TREML1 was detected in both the temporal cortex and cerebellum, while TREM2 159 
was reliably detected only in the temporal cortex. We validated TREML1 and TREM2 WG-160 
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DASL temporal cortex gene expression measurements, using RNAseq data generated from a 161 
subset of 93 autopsied AD subjects who also had microarray data. There was highly significant 162 
correlation between WG-DASL and RNAseq measurements for both TREML1 (rs=0.65, p<10
-40
) 163 
and TREM2 (rs=0.80, p<10
-40
) (Fig. S1).  164 
Variants located within 100kb of the 5’ or 3’end of any TREM coding gene that 165 
demonstrated association with AD-risk in the IGAP stage I meta-analysis (17,800 AD vs. 37,154 166 
controls, p0.0015), were evaluated for their association with TREML1 expression in the 167 
temporal cortex and cerebellum, and with TREM2 expression in the temporal cortex. Of the 168 
1,002 variants tested at this locus in the IGAP stage 1 meta-analysis, 28 had p-values  0.0015, 169 
and 16 of these have been genotyped in the autopsied samples in the Mayo Clinic brain 170 
expression genome-wide association study (Mayo eGWAS). We also assessed 5 other variants at 171 
this locus previously reported to be associated with either reduced AD-risk (rs3747742) [11], 172 
increased AD pathology burden and cognitive decline (rs6910730, rs7759295) [14], or decreased 173 
CSF tau levels (rs6916710, rs6922617) [13]. Table 2 shows the association of TREML1 and 174 
TREM2 gene expression with these 21 variants. In 399 combined AD and non-AD temporal 175 
cortex samples tested for the 16 IGAP variants, 5 SNPs showed association (uncorrected p<0.05) 176 
with increased levels of both TREML1 and TREM2 (rs9381040, rs2093395, rs9357347, 177 
rs9394778, rs9296359), and a sixth variant (rs9394767) was significantly associated with 178 
increased TREML1 levels only. As shown in Fig. 3, four of the six variants that associate with 179 
increased levels of TREML1 and TREM2 are in a single LD block (block 2: rs9357347, 180 
rs9381040, rs2093395 and rs9394767) and in tight linkage disequilibrium with each other 181 
(r
20.90). Of these variants, rs9381040 has the most significant AD-risk association in the IGAP 182 
stage 1 meta-analysis (Table 2). This IGAP “hit” is located 5.5kb downstream from TREML2 183 
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and 23.7kb upstream from TREM2 and is associated with TREML1 and TREM2 expression 184 
(p=0.0083, beta=0.086 and p=0.048, beta=0.091, respectively). Given that the expression 185 
measures were on a log2 scale, these changes in expression are equivalent to TREML1 and 186 
TREM2 fold-changes of 1.06 and 1.07, for each copy of the minor allele, respectively. Notably, 187 
the minor allele of the IGAP “hit” rs9381040 is associated with both decreased AD-risk and 188 
increased TREML1 and TREM2 levels. However, based on data from the Roadmap Epigenomics 189 
Consortium [22], rs9381040 lacks evidence of regulatory potential in brain regions relevant to 190 
AD.  191 
The variant with the most significant association with brain TREML1 expression, which 192 
also associates with TREM2 levels, is rs9357347 in block 2 (Fig. 3). This SNP is located 6.9kb 193 
downstream from TREML2 and 19.6kb upstream from TREM2 and is in tight LD with the IGAP 194 
“hit” rs9381040 (D’=0.99, r2=0.96). As expected, the minor allele of rs9357347 is associated 195 
with reduced AD-risk (OR=0.95, 95% CI=0.91-0.98, p=0.001) in the IGAP meta-analysis [12] 196 
and with increased TREML1 and TREM2 expression in the temporal cortex in the Mayo Clinic 197 
WG-DASL eQTL analysis (p=0.0063, beta=0.088 and p=0.046, beta=0.090, respectively) 198 
(Table 2 and Fig. S2). These beta coefficients can be interpreted as an estimated 1.06-fold 199 
change of both TREML1 and TREM2, per rs9357347 minor allele, in this temporal cortex 200 
dataset. Unlike the IGAP “hit” (rs9381040), rs9357347 lies within sequence subject to histone 201 
modifications and within a DNAse hypersensitive site detected by the Roadmap Epigenomics 202 
Consortium [22] in brain regions relevant to AD pathology such as the hippocampus. 203 
Furthermore, this variant is predicted to affect transcription factor binding (SP1 and PPAR) as 204 
catalogued in HaploReg (http://www.broadinstitute.org/mammals/haploreg/haploreg.php)  [23]. 205 
Consequently, it has a compelling Regulome score of 2b (http://www.regulomedb.org/) due to 206 
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the evidence of its regulatory potential [16] (Table 2). Indeed, of all the variants with an AD-risk 207 
p-value<0.0015 in the IGAP meta-analysis, and p-values<0.05 in our WG-DASL eQTL analysis 208 
of temporal cortex TREML1 and TREM2 gene expression levels, rs9357347 had the greatest 209 
regulatory potential as determined by their Regulome scores (Fig. S3 and Fig. S4). 210 
The other two variants with gene expression associations in the temporal cortex are in a 211 
different LD block (block 4: rs9394778 and rs9296359) and in tight LD with each other (r
2
 = 212 
0.67). These SNPs are more significantly associated with TREM2 than with TREML1 expression; 213 
however, neither has compelling evidence of regulatory potential as both have Regulome scores 214 
of 6 (Table 2). In the 374 AD and non-AD subjects with cerebellum expression measures, none 215 
of the 16 IGAP AD-risk associated variants that were tested, associate with TREML1 gene 216 
expression (p>0.05). 217 
We determined the extent of linkage disequilibrium (LD) between the likely regulatory 218 
variant rs9357347, the IGAP “hit” rs9381040 and the significant TREM2 rare missense AD-risk 219 
variants p.D87N (rs142232675) and p.R47H (rs75932628) [1]. As shown in Fig. 3, these two 220 
TREM2 rare missense AD-risk variants are not in LD with either rs9357347 or rs9381040. This 221 
suggests that the protective effect of the regulatory rs9357347 and the IGAP “hit” are 222 
independent of the rare, missense TREM2 variants.  223 
We next evaluated LD amongst variants tested at this locus, including  common TREM 224 
locus variants previously reported to have associations with AD-risk (rs3747742) [11], increased 225 
AD pathology burden and cognitive decline (rs7759295 and rs6910730) [14], or with lower CSF 226 
ptau (rs6922617 and rs6916710) [13]. The missense TREML2 variant rs3747742 (p.S144G) is in 227 
LD with the regulatory variant implicated in our study, rs9357347. As reported, rs3747742 is 228 
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also in LD with rs9381040 (IGAP hit); and as expected associates with reduced AD-risk 229 
(p=0.009), however with slightly lesser significance than the AD-risk association of the 230 
regulatory rs9357347 (p=0.001) or the IGAP “hit” rs9381040 (0.0006). Further, the association 231 
of rs3747742  with TREML1 expression is not as significant as that of rs9357347. In addition, 232 
rs3747742 has no association with brain TREM2 levels, and has a weak Regulome score of 6 233 
(Table 2).  234 
Of the four common TREM locus variants that associate with AD endophenotypes, only 235 
rs6916710 is in tight LD with the regulatory rs9357347 (D’=0.91, r2=0.62). However, 236 
rs6916710, does not show significant association with AD-risk in the IGAP meta-analysis 237 
(p=0.103) nor with TREML1 or TREM2 gene expression levels (Table 2).  238 
None of the other three common TREM locus variants with reported AD-endophenotype 239 
associations are in tight LD with the regulatory rs9357347 or any of the other TREM locus 240 
variants that are associated with AD-risk. Only rs7759295 showed association with TREML1 241 
gene expression (uncorrected p=0.04), but neither this nor any of the other AD-endophenotype-242 
associated SNPs have evidence of AD-risk association or Regulome scores that are indicative of 243 
likely regulatory function (Fig. 3 and Table 2). 244 
Utilizing publicly available RNAseq data from two independent cohorts (Table 1) that do 245 
not overlap with the samples included in the WG-DASL eQTL analysis, we sought replication of 246 
the rs9357347 association with TREML1 and TREM2. Although in the ROS/MAP RNAseq 247 
dataset a significant association was only detected with the levels of TREM2 (Table 3), meta-248 
analysis from the three independent study p-values (Mayo WG-DASL, Mayo RNAseq and 249 
ROS/MAP RNAseq) yielded significant results (TREML1 p=3.4x10
-2
; TREM2 p=3.5x10
-3
), 250 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
13 
 
confirming the association of the rs9357347 minor allele with increased TREML1 and TREM2 251 
gene expression. The evidence of association with TREM2 expression was greater upon meta-252 
analysis compared to the association observed in our discovery dataset; whereas the evidence of 253 
association with TREML1 expression was slightly greater in our discovery dataset compared to 254 
the meta-analysis. 255 
4. Discussion 256 
In this study, we first sought to characterize the brain expression of TREM locus genes 257 
based on the premise that those TREM cluster genes that are expressed in the brain are likely to 258 
be candidate AD-risk genes. We determined that besides TREM2, only TREML1 has reliable 259 
expression in the brain regions we studied. Whereas TREML1 is expressed in both cerebellum 260 
and temporal cortex of all subjects, TREM2 is expressed in 98% of temporal cortex and 41% of 261 
cerebellum samples. This suggests that cerebellar levels of TREM2 are lower than those for 262 
temporal cortex, consistent with previous reports showing higher gene levels in the temporal 263 
cortex than cerebellum [24] and higher protein levels correlating with AD neuropathology [25]. 264 
In contrast, TREM1, TREML2 and TREML4 are expressed in only 0%-17% of the subjects. 265 
While lack of reliable brain expression of these genes does not definitively rule them out as 266 
plausible AD-risk genes, our findings provide the strongest evidence for TREML1, besides 267 
TREM2, as most likely TREM locus genes for further studies in AD.  268 
Consequently, we focused our studies on TREML1 and TREM2; and utilized their brain 269 
expression levels as endophenotypes to identify putative regulatory variants that modify risk for 270 
AD. Focusing on brain TREML1 and TREM2 expression associations with variants at the TREM 271 
locus that also show evidence of AD-risk association in the publicly available IGAP meta-272 
analysis, we identified a putative regulatory variant, rs9357347, located between TREM2 and 273 
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TREML2. The minor allele of this variant is associated with both decreased AD-risk and with 274 
increased TREML1 and TREM2 brain expression in the temporal cortex. The direction of effect 275 
of this variant on AD-risk and brain expression levels of these genes appears to be biologically 276 
congruent based on the known functions of these genes.  277 
TREML1, which is also known as TREM-like transcript 1 (TLT-1), is a myeloid receptor 278 
expressed exclusively in the -granules of platelets and megakaryocytes [26]. Identification of 279 
higher levels of soluble TREML1 (sTLT-1) in septic patients vs. controls and development of 280 
hemorrhage in mice lacking Treml1 when exposed to inflammatory injury led to the conclusion 281 
that TREML1 functions to maintain vascular integrity during inflammation [27]. Further, 282 
TREML1 was shown to dampen leukocyte activation during sepsis, and inhibited pro-283 
inflammatory activation of TREM1 by competing with its ligand [28]. These studies strongly 284 
support a role for TREML1 in promoting vascular homeostasis and limiting inflammation.   285 
Functional, in-vitro studies of TREM2 rare, missense mutations revealed reduced TREM2 286 
function as a consequence of decreased maturation and ectodomain shedding, also supported by 287 
findings of decreased soluble TREM2 levels in the cerebrospinal (CSF) levels of patients with 288 
these mutations [13, 29]. TREM2 deficiency also led to increased amyloid pathology and 289 
neuronal loss in the 5XFAD mouse model of AD [30]. Interestingly, TREM2 deficiency in an 290 
ischemic mouse model resulted in reduced phagocytosis and resorption of infarcted brain tissue, 291 
and worse neurological recovery [31]. Collectively, these findings support a neuroprotective role 292 
for TREM2 in various neuronal injury models. There are, however, studies with contradictory 293 
results for TREM2. In a different mouse model of AD (APP/PS1), knock-out of Trem2, resulted 294 
in reduction of macrophages infiltrating from the periphery, along with less brain inflammation 295 
and reduced amyloid and tau pathology [32]. These opposite findings of Trem2 knock-out could 296 
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be due to differences in the mouse models of Alzheimer’s disease tested, different Trem2 297 
knockout mouse lines, and analyses performed at different time points (early stages versus later 298 
stages of Alzheimer’s disease). 299 
Given these collective data, a regulatory variant that enhances levels of TREML1 in 300 
platelets, and levels of TREM2 in brain resident microglia could conceivably promote vascular 301 
homeostasis and limit inflammatory damage to neurons in AD and potentially other nervous 302 
system diseases. Indeed, rs9357347 has compelling evidence of regulatory potential as it is 303 
located in a known DNase hypersensitive site and affects histone modification in the 304 
hippocampus and transcription factor binding, according to the evidence compiled in the 305 
Regulome database and HaploReg [16, 23]. Interestingly, rs9357347 is predicted to affect 306 
transcription factor binding (SP1 and PPAR) as catalogued in HaploReg. These two transcription 307 
factors are known be important in regulating key players in the inflammatory response and lipid 308 
metabolism [33, 34]. Further, rs9357347 shows the most significant association with TREML1 309 
gene expression amongst variants at the TREM locus with IGAP meta-analysis AD-risk p-310 
values0.0015, in addition to its association with brain TREM2 levels.  311 
The regulatory rs9357347 SNP is in the same haplotype block as the variant with the 312 
most significant AD-risk association at the TREM locus in the IGAP meta-analysis, rs9381040, 313 
which is an intergenic variant downstream of TREML2. Though this IGAP TREM locus “hit” 314 
SNP has greater evidence of AD-risk association than rs9357347, there is no evidence of 315 
regulatory potential for rs9381040 in brain regions relevant to AD.  316 
While the fold change estimates in gene expression associated with rs9357347-C are 317 
modest at 6-7%, the biological impact of the increase attributed to each copy of the minor allele, 318 
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can be significant and may provide sufficient protection from disease in some individuals, 319 
particularly when considered over a lifetime. Furthermore, these estimates are based on RNA 320 
isolated from tissue samples and not microglial cells where both TREM2 and TREML1 are 321 
predominantly expressed [35], and where expression levels of these genes may be impacted to a 322 
greater extent by regulatory variants. Additional studies will be needed to determine the impact 323 
of such expression changes on the biology of microglial cell function. 324 
The TREML2 p.S144G variant [11], which associates with reduced AD-risk, is also in LD 325 
with both rs9357347 and rs9381040. Though proposed to be the functional variant that accounts 326 
for the IGAP signal at this locus, TREML2 p.S144G is not predicted to have a functional 327 
consequence based on PolyPhen2 nor does it have evidence of regulatory potential. Further, 328 
TREML2 expression is too low to be reliably measured in brain tissue (TCX and CER). This 329 
raises the possibility that the association with TREML2 p.S144G is due to its LD with a 330 
functional variant(s) that influences the function or level of a nearby TREM gene(s), such as 331 
TREML1 or TREM2. Alternatively, the protective effect of p.S144G could be mediated directly 332 
through the function of TREML2 in a cell with abundant expression, such as macrophages, in 333 
which TREML2 is known to be upregulated in response to inflammation, [36]. It is also possible 334 
that significant rs9357347 eQTL associations would be detected with TREML2 or other TREM 335 
locus transcripts in tissues were these genes are more abundantly expressed. 336 
Our findings therefore challenge the conclusion that p.S144G is the only functional 337 
variant accounting for the protective effect detected in the IGAP meta-analysis at this locus, and 338 
propose rs9357347 as an alternative functional variant with regulatory effects. In reality, both 339 
variants could have functional consequences and contribute to the IGAP signal. It should be 340 
emphasized that, as demonstrated in our LD analysis, TREM2 p.R47H is not in LD with these 341 
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two variants, and thus affects AD-risk independently. Both rs9357347 and p.S144G should be 342 
tested for their functional potential and influence on outcomes of inflammation and 343 
neuroprotection. It remains possible that rs9357347 is in LD with an untested true functional 344 
variant with effects on transcription and AD-risk. It is likewise possible that while rs9357347 is 345 
associated with both AD-risk and gene expression levels, these joint effects are coincidental due 346 
to LD, rather than being related. These possibilities need to be explored through sequencing of 347 
the entire TREM locus, or via targeted sequencing of LD block 2 where rs9357347 resides. Thus, 348 
our findings provide a testable hypothesis for a strong candidate functional variant, specific 349 
transcription factors and their effects on TREML1 and TREM2 levels.    350 
Furthermore, our investigation of variants previously shown to associate with AD-related 351 
endophenotypes [13-15] suggests that these are unlikely to be functional AD-risk variants per se, 352 
though it remains possible that they are markers of functional variants at the TREM locus.  353 
In summary, we characterized expression of TREM genes in cerebellum and temporal 354 
cortex and determined TREML1 and TREM2 to be the only reliably expressed TREM genes in 355 
these brain regions. We identified rs9357347 as a putative regulatory variant that is associated 356 
with protection from AD and with increased TREML1 and TREM2 brain levels, and nominate 357 
rs9357347 as one of the functional variants that accounts for the IGAP AD-risk signal. 358 
Additional studies are needed to validate the function of this variant, and to explore the 359 
possibility of the presence of other variants at this locus that could contribute to associations 360 
observed with rs9357347.  Importantly, these findings suggest a potential link between TREML1 361 
and TREM2, as well as vascular homeostasis and neuroinflammation as related mediators of 362 
neuronal protection and injury in AD and possibly other central nervous system diseases. 363 
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 476 
Figure Legends 477 
Fig. 1. TREM gene cluster on Chr 6p21.1. The chromosomal positions are based on the human 478 
genome assembly from February 2009 (GRCh37/hg19). There are seven RefSeq genes at the 479 
TREM locus (TREM1, TREML1, TREM2, TREML2, TREML3P, TREML4 and TREML5P); 480 
however, TREML3P and TREML5P are non-coding pseudogenes. The transcript figures are 481 
taken from the UCSC Genome Browser. 482 
Fig. 2. Location of TREML1 and TREM2 WG-DASL probes. 483 
The location of the (A) TREML1 and (B) TREM2 WG-DASL probes (highlighted in light blue) 484 
are shown relative to their Refseq transcripts. The chromosomal positions are based on the 485 
human genome assembly from February 2009 (GRCh37/hg19). As shown, both of these probes 486 
are complementary to all RefSeq transcripts for the respective gene. The transcript figures are 487 
taken from the UCSC Genome Browser.  488 
Fig. 3. LD Plot of TREM locus variants. 489 
LD plot of TREM locus variants where haplotype blocks were determined with the solid spine 490 
definition; square colors correspond to D’ (tight LD=warmer colors, weak LD=cooler colors) 491 
and r
2
 values are shown within the squares (Supplementary Methods). Red circles: The rare 492 
TREM2 AD-risk missense variants rs142232675 (p.D87N) and rs75932628 (p.R47H) [1]. Blue 493 
circles: Variants that associate with increased AD pathology burden and cognitive decline 494 
(rs7759295 and rs6910730) [14], or with lower CSF ptau (rs6922617 and rs6916710) [13]. 495 
Green circles: The variant with the most significant AD-risk association in the IGAP meta-496 
analysis (rs9381040); rs9357347, which has the most significantTREML1 gene expression 497 
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association, also shows association withTREM2 gene expression, IGAP AD-risk association and 498 
the best Regulome score within all tested SNPs; and rs9296359 which has the most significant 499 
association with TREM2 expression. RefSeq gene transcripts are shown above the LD plot 500 
relative to the variant position according to the February 2009 human genome assembly 501 
(GRCh37hg19) across the targeted genomic region (TREM gene +/-100 kb: chr6:41016999-502 
41354457). 503 
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Tables 
Table 1. Description of samples included in the discovery and replication cohorts utilized for eQTL analysis. 
  
Mayo Clinic WG-DASL Mayo Clinic RNAseq ROS/MAP RNAseq 
CER TCX TCX PFCX 
AD Non-AD AD  Non-AD AD  non-AD  AD non-AD 
N 197 177 202 197 84 48 288 206 
Mean age +/- SD 73.6 ± 5.6 71.7 ± 5.5 73.6 ± 5.5 71.6 ± 5.6 83.2 ± 8.7 85.7 ± 8.3 89.8 ± 5.8 86.5 ± 7.2 
Female, N (%) 101 (51%) 63 (36%) 108 (53%) 78 (40%) 48 (57%) 26 (54%) 186 (65%) 121 (59%) 
% APOE 4+ 64% 25% 61% 25% 51% 17% 34% 12% 
 
Samples included in the Mayo Clinic eGWAS (discovery cohort), with cerebellar (CER) and temporal cortex (TCX) gene expression 
measurements from Illumina WG-DASL arrays have been previously described [17]. Samples in the Mayo Clinic RNAseq cohort 
(replication cohort #1) had temporal cortex gene expression measurements, and did not overlap with the Mayo eGWAS (WG-DASL) 
cohort. The ROS/MAP RNAseq cohort (replication cohort #2) had dorsolateral prefrontal cortex (PFCX) gene expression 
measurements, and did not overlap with the Mayo eGWAS (WG-DASL), or with the Mayo Clinic RNAseq cohort. The RNAseq data 
for these two cohorts is available at the Sage Synapse, AMP AD Knowledge Portal 
(https://www.synapse.org/#!Synapse:syn2580853/wiki/66722), under synapse IDs syn3388564 (ROS/MAP RNAseq) and syn3163039 
(Mayo RNAseq). 
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Table 2. Association of variants at the TREM locus with AD-risk and TREM WG-DASL brain gene expression levels. 
  
 
 
Chr SNP 
Position  
hg19 
AD-Risk (IGAP Stage1 Meta-analysis) Brain eQTL (Mayo Clinic eGWAS) 
Regulome
Score 
HapMap CEU    
MAF Effect 
Allele 
Non 
Effect 
Allele 
OR (95% CI) P-value 
TREML1 
CER 
BETA 
TREML1 
CER        
P 
TREML1 
TCX 
BETA 
TREML1 
TCX        
P 
TREM2 
TCX 
BETA 
TREM2 
TCX         
P 
6 rs9381040 41,154,650 T C 0.94 (0.91 - 0.98) 5.97E-04 0.021 2.30E-01 0.086 8.30E-03 0.091 4.80E-02 NA 26.70% 
6 rs2093395 41,155,026 C G 0.94 (0.91 - 0.98) 6.40E-04 0.021 2.30E-01 0.086 8.30E-03 0.091 4.80E-02 6 27.90% 
6 rs2038568 41,158,132 C G 1.14 (1.05 - 1.23) 7.93E-04 0.018 7.80E-01 -0.08 3.90E-01 -0.186 1.60E-01 5 8.30% 
6 rs12194214 41,028,574 C A 1.16 (1.06 - 1.26) 8.36E-04 -0.081 9.40E-02 -0.104 2.70E-01 -0.129 3.20E-01 6 4.20% 
6 rs9462675 41,153,238 A G 1.15 (1.06 - 1.25) 9.54E-04 -0.015 7.50E-01 -0.114 1.60E-01 -0.207 6.50E-02 5 3.60% 
6 rs6933067 41,133,522 C T 1.15 (1.06 - 1.25) 1.07E-03 -0.013 7.60E-01 -0.098 2.10E-01 -0.134 2.10E-01 7 3.50% 
6 rs9357347 41,150,591 C A 0.95 (0.91 - 0.98) 1.10E-03 0.013 4.60E-01 0.088 6.30E-03 0.09 4.60E-02 2b 28.10% 
6 rs9394767 41,159,905 G A 0.95 (0.91 - 0.98) 1.14E-03 0.011 5.70E-01 0.096 6.50E-03 0.083 1.00E-01 5 28.80% 
6 rs1542638 41,286,604 G A 1.06 (1.02 - 1.09) 1.14E-03 -0.022 2.20E-01 -0.035 2.90E-01 -0.064 1.60E-01 4 28.30% 
6 rs9471491 41,153,622 A C 1.15 (1.05 - 1.26) 1.31E-03 -0.015 7.50E-01 -0.114 1.60E-01 -0.207 6.50E-02 7 3.50% 
6 rs9471495 41,157,372 A C 1.15 (1.05 - 1.25) 1.40E-03 0.014 8.30E-01 -0.099 2.90E-01 -0.235 7.20E-02 7 3.50% 
6 rs9462677 41,158,856 A T 1.15 (1.05 - 1.25) 1.41E-03 0.016 8.10E-01 -0.099 2.90E-01 -0.235 7.30E-02 7 4.30% 
6 rs9394778 41,215,058 A G 0.95 (0.92 - 0.98) 1.44E-03 0.015 3.30E-01 0.065 2.70E-02 0.099 1.50E-02 6 39.80% 
6 rs9471494 41,157,344 G C 1.15 (1.05 - 1.25) 1.46E-03 0.01 8.70E-01 -0.102 2.60E-01 -0.221 8.20E-02 6 4.50% 
6 rs6912013 41,061,593 C T 1.15 (1.05 - 1.25) 1.48E-03 -0.076 1.20E-01 -0.104 2.70E-01 -0.124 3.40E-01 5 2.70% 
6 rs9296359 41,205,690 A G 0.95 (0.92 - 0.98) 1.48E-03 0.017 2.80E-01 0.066 2.40E-02 0.116 4.60E-03 6 27.40% 
6 rs3747742* 41,162,518 C T 0.96 (0.92 - 0.99) 8.56E-03 0.018 2.90E-01 0.072 2.30E-02 0.064 1.50E-01 6 28.30% 
6 rs6916710* 41,164,788 T C 0.97 (0.94 - 1.01) 1.03E-01 0.013 4.30E-01 0.054 7.70E-02 0.072 9.20E-02 7 38.40% 
6 rs7759295* 41,135,850 T C 0.98 (0.93 - 1.03) 3.66E-01 -0.023 3.50E-01 0.094 4.00E-02 -0.008 9.00E-01 6 13.30% 
6 rs6910730* 41,246,633 G A 0.99 (0.94 - 1.04) 6.86E-01 -0.046 8.50E-02 -0.079 1.20E-01 -0.032 6.50E-01 4 8.40% 
6 rs6922617* 41,336,101 A G 0.99 (0.93 - 1.05) 6.98E-01 -0.033 2.60E-01 -0.098 7.40E-02 0.011 8.90E-01 7 8.50% 
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Shown are variants located within 100kb of a TREM gene that had an AD-risk p  0.0015 in the IGAP stage 1 meta-analysis (top 16 
rows), as well as 5 common TREM locus variants with previous reports of AD-risk or endophenotype association (bottom 5 rows, SNP 
marked with an *). AD-risk association results are from the publicly available IGAP meta-analysis stage 1. Brain gene expression 
associations are from the Mayo Clinic eGWAS and based on cerebellar (CER) and temporal cortex (TCX) gene expression 
measurements with Illumina WG-DASL arrays with TREML1 probe ILMN_1690783 and TREM2 probe ILMN_1701248. Variants 
showing association with gene expression (uncorrected p<0.05) are underlined and in italic font. The variant with the most significant 
AD-risk association in the IGAP meta-analysis (rs9381040), and the variant with the most significant gene expression association and 
best Regulome score (rs9357347) are in bold font. OR (95% CI): odds ratio and 95% confidence interval. Given that the eGWAS 
expression measures were on a log2 scale, fold-change for the Mayo eGWAS beta coefficients = 2
beta
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Table 3. Meta-analysis of rs9357347 eQTL results from three independent datasets.  
Dataset 
Sample 
size 
MAF 
TREML1  TREM2 
beta SE p  beta SE p 
Mayo WG-DASL 380 0.307 0.088 0.032 6.28E-03 
 
0.090 0.045 4.61E-02 
Mayo Clinic RNAseq 132 0.311 -0.030 0.108 7.82E-01  0.084 0.128 5.13E-01 
ROS/MAP RNAseq 494 0.281 0.089 0.114 4.36E-01  0.124 0.060 3.77E-02 
Meta-analysis 1006   +-+   3.36E-02  +++   3.54E-03 
 
Meta-analysis of rs9357347 eQTL results from temporal cortex (Mayo WG-DASL and Mayo 
Clinic RNAseq) and dorsolateral prefrontal cortex samples (ROS/MAP). MAF = minor allele 
frequency. SE = standard error. Since in all three datasets the expression measures analyzed were 
on a log2 scale, fold-change for the beta coefficients = 2
beta
. The meta-analysis was performed 
using METAL, with weighted average of z-scores from the individual study p-values, weighted 
according their sample size. 
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Research in Context 
Systematic review: We performed a comprehensive review of existing literature investigating 
the role of the TREM locus in AD. Although the involvement of TREM genes in AD 
pathophysiology and the underlying variants modifying AD-risk remain unclear, there have been 
several studies demonstrating association with AD risk and its endophenotypes. 
Interpretation: We hypothesized that some variants at the TREM locus may modify AD-risk via 
regulation of TREM gene expression. We found a variant in a regulatory region (rs9357347-C) at 
the TREM locus that associates with reduced AD risk and higher TREML1 and TREM2 brain 
gene expression.    
Future directions: Our findings nominate regulation of brain TREML1 and TREM2 as a 
potential mechanism for AD risk modification by TREM locus variants. In-depth sequencing of 
the TREM locus is needed to fully characterize regulatory variants at this locus that may modify 
AD-risk. 
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 TREM2 and TREML1 are the only TREM cluster genes with reliable brain expression. 
 Higher brain levels of TREM2 and TREML1 associate with rs9357347-C. 
 rs9357347 is predicted to affect transcription factor binding (SP1 and PPAR). 
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Responses to Reviewers 
 
We provide in this document point-by-point responses to each of the comments by our 
Reviewers. The order follows that in the original “Comments” letter we received on 07-09-2016. 
The original text from the Editor or Reviewers is shown “within quotation marks with  italicized 
Calibri font”. Changes made to the manuscript to address reviewer’s comments are highlighted in 
yellow, both on the manuscript and on the responses below. The location of changes made to the 
manuscript is indicated relative to the “changes-accepted” version of the manuscript files, and 
these locations are highlighted in blue to facilitate the review. We also added line numbers to the 
Main and Supplementary manuscript files. We are extremely grateful for the thoughtful and 
thorough reviews of our manuscript. We were delighted to receive many positive comments and 
believe that the changes that we made in response to each of the comments have further 
strengthened our manuscript.      
Reviewers' comments: 
“This paper reports the results of a comprehensive and innovative study of common Alzheimer's disease 
(AD) risk variants at the TREM locus.  Notably, the study tests the hypothesis that some of the common 
AD‐risk variants at the TREM  locus confer disease risk via regulation of transcript  levels of some of the 
coding genes at the TREM gene cluster.  This work is significant both for the TREM locus and potentially 
as  a  more  general  approach  for  other  AD‐risk  loci.   Strengths  of  the  study  include  the  strong 
replication/validation  strategy  and  the  focus  on  identification  and  characterization  of  functional 
regulatory genetic variants.” 
We thank the reviewers for their many favorable comments, including those which indicated that 
the paper “is well written”, “has an interesting finding”, is “based on well characterized IGAP and Mayo 
Clinic  cohorts  with  adequate  study  sizes”, and that “The  expression  association  analysis  was  well 
designed  and  thoroughly  executed” with  “appropriate  replication  cohorts”. Importantly, one of the 
reviewers stated that “The study contributes to the understanding of the broader role of TREM locus in 
AD”. 
 
“The  reviewers have  raised  several major and numerous minor points  that must be addressed  for  the 
paper to be considered for publication in the Journal.  Many of the points are focused on clarification of 
the statistical analysis and  interpretation of the results.   These concerns must be addressed to  improve 
Carrasquillo_etal_TREM_Response_To_Reviewers_08-18-2016
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the  statistical  rigor  of  the  analysis  and  reflect  the  findings  and  conclusions  reported  in  the  paper.” 
 
We have addressed the concerns point by point below.  
 
 
Reviewer #1: 
 
Comment 1: 
“The paper has an  interesting  finding  that a  functional  regulatory  variant  contributes  to a protective 
effect observed  in  the TREM1  IGAP GWAS meta‐analysis  (even  though not  significant at 10‐8 nominal 
level) and suggests concomitant increase in TREM1 and TREM2 brain levels. This study was based on well 
characterized IGAP and Mayo Clinic cohorts with adequate study sizes.” 
 
We thank this Reviewer for their positive comments.   
 
“However, the paper needs several clarifications. 
  
Major Comments: 
  
1.    Can the authors give a sense of variation explained by their variant in terms of AD pathology?” 
 
We sincerely appreciate this reviewer’s thorough evaluation of our manuscript, and the rigor 
implemented in their assessment of our results.  
 
To address this reviewer’s first comment,  we evaluated the effect of this variant on Braak stage 
using both ANOVA and linear regression models described on the Supplementary Material, page 
8, 2nd paragraph, and in Table S4, as shown below: 
 
“Given the association of rs9357347 with AD-risk, we tested the hypothesis that this variant 
could also show an association with Braak stage, as the latter is an important criterion for the 
neurophathological diagnosis of AD [14]. Implementing an ANOVA model in R that included 
age-at-death, sex and APOE 4 dose (0, 1 or 2 alleles), in the two larger datasets (Mayo WG-
DASL and ROS/MAP RNAseq), we determined that rs9357347 does not significantly contribute 
to the variance in Braak stage in either of these two cohorts (p=0.91 and p=0.27, respectively). In 
addition, we implemented linear regression analysis in R, again using the two larger datasets to 
estimate the effect of each copy of the rs9357347 minor allele on Braak stage, including age-at-
death, sex and APOE 4 dose in the model. As shown in Table S4, we did not detect a 
significant association of rs9357347 with Braak stage in either cohort.” 
 
Dataset  N  beta  SE  p‐value  
Mayo WG‐DASL: Temporal Cortex  399  ‐0.139  0.160  0.387 
ROS/MAP RNAseq: DFPC  492  0.053  0.081  0.515 
              
Table  S4.  Association  of  rs9357347  with  Braak  stage.  The  two  largest 
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cohorts  were  evaluated:  Mayo  WG‐DASL  and  ROS/MAP  RNAseq.  The 
variant was tested for association with Braak stage using  linear regression 
under an additive model and including age‐at‐death, sex and APOE 4 dose 
as  covariates.  In  this  model,  the  beta  coefficient  is  interpreted  as  the 
change  in Braak  score associated with each  copy of  the minor allele. N = 
sample size.  SE= standard error.  DFPC = dorsolateral prefrontal cortex. 
 
 
Comment 2: 
“2.      Authors use  the word "nominally significant." This  term  is generally used  for associations on  the 
borderline. A p‐value of 10‐3 does not meet this threshold in a GWA study (Table 2). Can the authors use 
a different term, such an association of potential interest given your scientific hypothesis rather than this 
being somehow data driven.” 
  
We used the term “nominally significant” when referring to an uncorrected p-value < 0.05. We 
have now modified the language wherever the term “nominally significant” was used, as shown 
below:  
 
Page 4, 3rd paragraph, 2nd sentence: “…the intergenic variant, rs9381040, that demonstrated the 
most significant association at the TREM locus in the IGAP AD-risk GWAS meta-analysis 
(uncorrected p=6x10-04) [12].” 
 
Page 9, 2nd paragraph, 5th sentence: “…5 SNPs showed association (uncorrected p<0.05) with 
increased levels of both TREML1 and TREM2…” 
 
Page 12, 3rd paragraph, 2nd sentence: “Only rs7759295 showed association with TREML1 gene 
expression (uncorrected p=0.04),...” 
 
Page 25, Table 2 legend, 4th sentence: “Variants showing association with gene expression 
(uncorrected p<0.05) are underlined and in italic font.” 
 
Comment 3: 
“3.      What do the authors mean by non‐AD subjects  (abstract)? Do they mean neurological conditions 
other than AD, or subjects who did not have any AD pathology, as in not cognitive impaired? If the study 
had no controls, or not cognitive  impaired subjects, does conditioning on  the disease status cause any 
bias due to conditioning on a collider? For example, Cole et al.,  Int J Epidemiol. 2010. 39:417‐420. This 
may not apply but is of interest given the conditioning statement.” 
 
In the post-mortem cohorts that were utilized in this study, non-ADs are those subjects whose 
neuropathological diagnoses did not meet criteria for definite AD, but they could have other 
unrelated neuropathologies. In our original submission, the diagnostic criteria for the Mayo 
Clinic WG-DASL eQTL dataset are indicated on the 1st paragraph on page 3 of the 
Supplementary Material and the reference is supplied in the Main Manuscript, page 7, 1st 
paragraph; that for the Mayo Clinic RNAseq dataset is mentioned on 2nd paragraph on page 4 of 
the Supplementary Material, and on the Main Manuscript, on page 7, 2nd paragraph; and 
references are supplied for the ROS/MAP cohort in the Main Manuscript, page 7, paragraph 2. 
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To clarify the diagnostic criteria in the main text, we now include in the Main Manuscript, page 
7, 1st paragraph, the following text: 
 
All AD subjects had neuropathological diagnosis of definite AD [2]. The non-AD subjects did 
not fulfill neuropathological criteria for definite AD, but many had other unrelated pathologies.   
 
We also added the same references for the ROS/MAP dataset to the Supplementary Text, page 5, 
3rd paragraph, for consistency. 
 
 
As the primary goal of this study was to estimate the effect of genetic variants on gene 
expression, rather than their effect on disease status, we combined ADs and non-ADs in the 
linear regression analysis and included diagnosis as a covariate. The diagnosis covariate was 
coded as the presence or absence of AD. Our original submission described this analytic 
methodology in the Supplementary Material, “Mayo Clinic WG-DASL eQTL dataset” sub-
section, formerly last paragraph, and in the now deleted “eQTL analysis of rs9357347 and 
TREML1/TREM2 RNAseq gene expression” subsection, last sentence. The analytic methodology 
is instead included in the Main Manuscript in this revision for clarity. We now include a “2.4 
Statistical Analysis” sub-section, in the Main Text, pages 7-8, shown below. In doing so, we also 
address Comment #2 of Reviewer #5.   
 
2.4. Statistical Analysis 
Normalized transcript expression levels, on a log2 scale, were tested for associations with 
TREM locus genotypes in each of the three datasets (Mayo WG-DASL, Mayo Clinic RNAseq 
and ROS/MAP RNAseq) via multivariable linear regression analyses implemented in PLINK 
[20]. An additive model was applied adjusting for age-at-death, sex, diagnosis, RNA Integrity 
Number (RIN) and adjusted RIN squared (RIN-RINmean)2 in all expression analyses, and APOE 
4 dosage and PCR plate in Mayo WG-DASL only, and flowcell in the Mayo Clinic RNAseq 
dataset only. The eQTL analysis in the discovery, WG-DASL dataset, included APOE 4 dose as 
a covariate given the strong effect of this allele on AD. However, since a significant association 
was not detected with this covariate in the rs9357347 eQTL analyses in the discovery set, APOE 
4 dose was not included in the eQTL analyses implemented on the replication cohorts. For 
comparison, we have performed the eQTL analyses in all three datasets with and without 
adjustment for APOE 4 dose and do not observe a substantial difference in the association 
results between these two models. 
Meta-analyses were performed on eQTL results from the three independent datasets. For 
these analyses, METAL [21] was implemented using weighted average of z-scores from the 
individual study p-values, weighted according their sample size. 
  
 
To address Comment #3 of our Reviewer #1, we also investigated the possibility of “collider 
conditioning bias" in our analyses. In the article by Cole et al. cited by this reviewer, the term 
"collider conditioning bias" refers to the bias that occurs when conditioning, adjusting or 
stratifying on a common effect of the “exposure” and “outcome” being measured. In our study, 
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the potential for collider conditioning bias arises if both the genotype and the expression levels 
are associated with disease status. “Collider conditioning bias” could be a potential issue in our 
study design, because we adjusted for disease status (disease status potentially being the 
“collider”, i.e. a common effect of genotype and expression level). Therefore, in addition to 
analyzing the AD and non-ADs together (AD+nonAD) and adjusting for AD status, we have 
also now analyzed the combined set of AD+nonAD, without adjustment for disease status, in 
order to determine if the effect of genotype on expression disappears or remains in the latter 
analysis.  
 
We include this new analysis, which revealed lack of evidence of “collider conditioning bias”, as 
shown below and on page 7 of the Supplementary Material, and in Table S2 on page 15: 
 
Assessment of potential collider conditioning bias 
 
“Since the primary goal of this study was to estimate the effect of genetic variants on gene 
expression, rather than their effect on disease status, we combined ADs and non-ADs in the 
linear regression analysis and included diagnosis as a covariate. The diagnosis covariate was 
coded as the presence or absence of AD. However, adjusting for diagnosis status could 
potentially introduce a collider conditioning bias if both the genotype and the expression levels 
are associated with disease status [13]. Therefore, we have also analyzed the combined set of 
AD+nonAD, without adjustment for disease status, in order to determine if the effect of genotype 
on expression disappears or remains in the latter analysis. Table S2, shows results for the two 
types of analyses that were performed in each of the three datasets (Mayo WG-DASL, Mayo 
RNAseq and ROS/MAP RNAseq): (1) AD and nonAD combined while adjusting for diagnosis, 
(2) AD and nonAD combined not adjusting for diagnosis. Overall, the results from analyses 1 
and 2 are very similar, suggesting that there is no real impact of a collider effect.” 
         TREML1  TREM2 
Dataset  Group  N  beta  SE  p‐value   beta  SE  p‐value  
Mayo WG‐DASL:       
Temporal Cortex 
All (W/Dx)a  380  0.088  0.032  6.28E‐03  0.090  0.045  4.61E‐02 
All (Wo/Dx)b  380  0.083  0.033  1.32E‐02  0.088  0.045  5.33E‐02 
Mayo Clinic RNAseq: 
Temporal Cortex 
All (W/Dx)a  132  ‐0.030  0.108  7.82E‐01  0.084  0.128  5.13E‐01 
All (Wo/Dx)b  132  ‐0.023  0.111  8.40E‐01  0.102  0.145  4.86E‐01 
ROS/MAP RNAseq: 
DFPC 
All (W/Dx)a  494  0.089  0.114  4.36E‐01  0.124  0.060  3.77E‐02 
All (Wo/Dx)b  494  0.089  0.114  4.35E‐01  0.125  0.060  3.81E‐02 
                          
Table  S2. Analyses  to  assess  the  potential  of  introducing  collider  conditioning  bias  in  the  linear 
regression model due to adjustment for diagnosis. For each of the three datasets,  linear regression 
analysis was run in a: AD and non‐AD combined, with diagnosis included as a covariate; b: Analysis of 
AD and non‐AD combined, without adjustment  for diagnosis.   N =  sample  size. SE=  standard error. 
DFPC = dorsolateral prefrontal cortex. Given that all expression measures were on a log2 scale, fold‐
change for the beta coefficients = 2beta. 
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Comment 4: 
“4.    Page 4, Paragraph 2, states that the meta‐analysis was done in AD cases and controls. I am not sure 
if the authors are somehow use controls and non‐AD in an exchangeable fashion.” 
 
 
The sentence referred to by our Reviewer states “Since the first two reports [1, 2], the risk effect 
of the most significant TREM2 rare missense variant p.R47H (a.k.a. rs75932628) has been 
replicated in multiple Caucasian series [5-9], including a large meta-analysis of 24,086 AD cases 
and 148,993 controls [10]”, where the meta-analysis refers to published case-control analysis.  
 
In contrast, throughout the manuscript, we consistently used the term non-AD to refer to subjects 
included in our eQTL analyses whose neuropathological diagnosis was not consistent with AD. 
Hence, we did not use non-AD and control in an exchangeable fashion.  
 
Comment 5: 
“5.      Since  the cohorts  for this study have other cognitive phenotypes, do these  findings replicate with 
cognitive phenotypes?” 
 
Cognitive phenotypes were available only for the ROS/MAP cohort. Measures from this cohort 
of global cognitive decline and global cognition at the last evaluation before death were tested 
for association with rs9357347. As shown below, and on the Supplementary Material, pages 8, 
last paragraph, and in Table S5, we did not detect a significant association of this variant with 
either of these two phenotypes: 
 
“We also evaluated the association of rs9357347 with measures of global cognitive decline and 
global cognition at the last evaluation before death in the ROS/MAP cohort. In this dataset, 
global cognition is a variable for overall cognitive function measured by the raw scores from 19 
different tests that are converted to z scores and averaged. Global cognitive decline is a 
longitudinal cognitive phenotype based on repeated measures of global cognition, as previously 
described [15, 16]. The analysis was performed using linear regression analysis implemented in 
R, under an additive model for rs9357347, and adjusting for age-at-death, sex and APOE 4 
dose. Neither global cognitive decline nor global cognition at last evaluation shows an 
association with rs9357347 in this cohort (Table S5).”  
 
Phenotype  N  beta  SE  p‐value  
Global cognitive decline  470  ‐0.007  0.007  0.320 
Global cognition at last visit  493  ‐0.058  0.071  0.418 
              
Table  S5.  Association  of  rs9357347  with  cognition.  Measures  of 
cognition that were available in the ROS/MAP cohort were tested for 
association with rs9357347 using linear regression under an additive 
model,  including age‐at‐death, sex and APOE 4 dose as covariates. 
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N = sample size. SE = standard error.  Z scores of the cognitive scores 
were  analyzed,  thus  the  beta  coefficients  can  be  interpreted  as 
changes in z‐score associated with each copy of the minor allele. 
 
 
Comment 6: 
“6.    Page 5, Paragraph 2, Line 27‐35. I am not clear what the authors are stating here. Are they stating 
that  their study did not  replicate  for  the  two variants, because of a variant  that has not been defined 
functionally. Please clarify.” 
 
To contextualize this comment, we provide here the original version of this paragraph and show 
in bold font the line questioned by our Reviewer:  
 
“Some variants at the TREM locus have been reported to associate with AD endophenotypes. 
Cerebrospinal fluid (CSF) levels of AD biomarkers, tau and ptau, associate with three variants at 
the TREM locus that are not in LD with each other: TREM2 p.R47H (rs75932628), rs6916710 
located in intron 2 of TREML2, and rs6922617 located downstream from NCR2 and outside the 
TREM cluster. Of these variants, only TREM2 p.R47H was associated with AD-risk [13]. More 
recently, a variant upstream of TREM2 (rs7759295) and a variant in intron 3 of TREM1 
(rs6910730) were reported to independently associate with increased AD pathology burden and 
increased rate of cognitive decline [14]. However, neither of these two variants shows 
association with AD-risk in the IGAP meta-analysis (p>0.05) [15]. Thus, it is possible that 
the effect observed with these variants on AD endophenotypes is due to their LD with an as 
yet defined functional variant(s) that influences AD-risk at the TREM locus.”  
 
 
In this above former version of this paragraph, we summarized previously reported associations 
of variants at the TREM locus with AD endophenotypes. On the last 2 sentences of this 
paragraph we intended to explain that since these variants do not any show association with AD-
risk in the IGAP meta-analysis (p>0.05), it is possible that these variants themselves are not 
affecting AD endophenotypes, but are instead reflecting the association of a nearby functional 
variant, that is in LD with them and which, if tested, would show association with both AD-risk 
and endophenotypes. In order to clarify this point, we have modified this paragraph on page 5 as 
follows: 
 
“Some variants at the TREM locus have been reported to show association with AD 
endophenotypes [11, 13, 14]. Cerebrospinal fluid (CSF) levels of AD biomarkers, tau and ptau, 
associate with three variants at the TREM locus that are not in LD with each other: TREM2 
p.R47H (rs75932628), rs6916710 located in intron 2 of TREML2, and rs6922617 located 
downstream from NCR2 and outside the TREM cluster. Of these variants, only TREM2 p.R47H 
was associated with AD-risk [13]. More recently, a variant upstream of TREM2 (rs7759295) and 
a variant in intron 3 of TREM1 (rs6910730) were reported to be independently associated with 
increased AD pathology burden and increased rate of cognitive decline [14]. However, neither of 
these two variants shows association with AD-risk in the IGAP meta-analysis (p>0.05) [15]. 
Thus, other than TREM2 p.R47H, none of the TREM locus variants previously reported to 
associate with AD endophenotypes show association with AD-risk. Functional ADrisk variants 
that influence AD endophenotypes are expected to show association both with these 
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endophenotypes and risk of AD. Therefore, it is possible that these latter variants are not the 
functional variants per se, but merely markers of other un-tested functional variants.”  
 
 
Comment 7: 
“7.      Variant  Selection  (Section 2.1). Please  clarify what  you mean by  "strength". A p‐value does not 
provide strength of the association, but merely an error rate beyond the nominal value.” 
 
We agree with this comment, and note that we used the word “strength” twice in the manuscript 
in relation to a p-value. In both instances it was used to denote the “strength of the evidence”. 
Therefore, we have modified the sentences that originally used the word “strength” as follows: 
 
Page 6, 2nd paragraph, 2nd sentence: “Variants were further selected based on the statistical 
significance of their AD-risk association in the IGAP stage 1 meta-analysis [12] 
(Supplementary Methods), where only those variants with p-values  0.0015 were kept.” 
 
Page 13, 1st paragraph, last sentence: “The evidence of association with TREM2 expression was 
greater upon meta-analysis compared to the association observed in our discovery dataset; 
whereas the evidence of association with TREML1 expression was slightly greater in our 
discovery dataset compared to the meta-analysis.” 
 
 
Comment 8: 
“8.      The Mayo  clinic WG‐DASL  samples were  from  participants who were  younger  than Mayo  clinic 
RNAseq and ROS/MAP RNAseq. Does age have any association with the expression levels? (Table 1)” 
 
We now address this on the Supplementary Material, page 9, 2nd paragraph, as shown below: 
 
“Association of age with TREML1 and TREM2 expression 
As the WG-DASL cohort was overall younger than the two RNAseq cohorts, we assessed 
the association of the age covariate on TREML1 and TREM2 gene expression levels in the linear 
regression model described in the Material & Methods section 2.4. Age was not significantly 
associated with either TREML1 or TREM2 expression in the Mayo WG-DASL cohort (p>0.05). 
On the other hand, both in the Mayo RNAseq and ROS/MAP RNAseq cohorts, TREML1 and 
TREM2 expression levels appeared to be slightly increased with age, albeit the magnitude of the 
effect sizes were modest, with beta coefficients equivalent to approximately a 1.01 and 1.03-fold 
change in expression levels (Mayo RNAseq: TREML1 p=0.085, beta=0.01; TREM2 p=0.026, 
beta=0.02. ROS/MAP RNAseq: TREML1 p=2.0x10-3, beta=0.04; TREM2 p=4.4x10-5, 
beta=0.03). Since TREML1 and TREM2 gene expression levels appear be increased with age, it 
is possible that this might have led to a decrease in power to detect an association of rs9357347-
C with increased levels of these genes in the two older cohorts.” 
 
Comment 9: 
“9.    Can you provide an interpretation for your "beta" coefficient on Page 7, last line of Paragraph 1 of 
the Results?” 
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We apologize for the confusion caused by the “beta” symbol that was mistakenly used in that 
sentence. The symbol should have been “rs”, representing a Spearman’s rank correlation 
coefficient, as we now indicate it on page 9, 1st paragraph, last sentence: 
 
“There was highly significant correlation between WG-DASL and RNAseq measurements for 
both TREML1 (rs=0.65, p<10-40) and TREM2 (rs=0.80, p<10-40) (Fig. S1).” 
 
 
Comment 10: 
“10.    Page 7 last line. Is the nominal p‐value "0.0015"? How did you arrive that this significance level?” 
 
We now explain the rationale for this cut-off in the Materials and Methods, 2.1 Variant selection 
section, page 6, 3rd sentence: 
 
“This p-value cut-off was arbitrarily chosen to select those variants that existed in both the IGAP 
stage 1 AD GWAS and in our discovery eQTL cohort, Mayo Clinic Whole Genome-DASL 
dataset, and that could be genotyped, if needed, in the replication eQTL cohorts, using cost-
effective, medium-throughput assays.”   
 
 
Comment 11: 
“11.      Page 8, Line 26. The variant rs9381040  is not associated with TREM1 CER, but only with TREM1 
TCX, and at the borderline for TREM2 TCX. The word "strongest" appears 32 different times throughout 
the manuscript.”  
 
We agree with this reviewer’s assessment of the modest evidence of association for rs9381040 
with TREML1 and TREM2 brain expression levels, despite this variant having the most 
significant p-value of AD risk association at the TREM locus in the IGAP meta-analysis. This is 
in contrast to rs9357347, which is in LD with rs9381040, and which has both evidence of 
association with AD risk and brain expression. Indeed, we emphasize this point in the Discussion 
section, page 15, 3rd paragraph as follows:    
 
“The regulatory rs9357347 SNP is in the same haplotype block as the variant with the most 
significant AD-risk association at the TREM locus in the IGAP meta-analysis, rs9381040, which 
is an intergenic variant downstream of TREML2. Though this IGAP TREM locus “hit” SNP has 
greater evidence of AD-risk association than rs9357347, there is no evidence of regulatory 
potential for rs9381040 in brain regions relevant to AD.” 
 
We note that in many of the instances where the terms “strong” and “strongest” were used in our 
manuscript, they were in relation to the p-value of association for rs9381040 with AD-risk in the 
IGAP stage 1 meta-analysis and not its association with brain gene expression levels. 
Nevertheless, we do acknowledge that the words strong and strongest could be substituted with 
other adjectives. Therefore, we have edited this word on 25 occasions, as in the following 
examples:  
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Page 4, 3rd paragraph, 2nd sentence: “TREML2 p.S144G is in tight LD with the intergenic variant, 
rs9381040, that demonstrated the most significant association at the TREM locus in the IGAP 
AD-risk GWAS meta-analysis (p=6x10-04) [12].” 
 
Page 9, 2nd paragraph, penultimate sentence: “Of these variants, rs9381040 has the most 
significant AD-risk association in the IGAP stage 1 meta-analysis (Table 2).” 
 
 
Comment 12: 
“12.    For the sake of clarity, please provide an interpretation for "beta" throughout the manuscript.” 
 
We now provide an interpretation for the beta coefficients throughout the manuscript, as in the 
following examples: 
 
Page 10, 2nd sentence was added as follows: “This IGAP “hit” is located 5.5kb downstream from 
TREML2 and 23.7kb upstream from TREM2 and is associated with TREML1 and TREM2 
expression (p=0.0083, beta=0.086 and p=0.048, beta=0.091, respectively). Given that the 
expression measures were on a log2 scale, these changes in expression are equivalent to 
TREML1 and TREM2 fold changes of 1.06 and 1.07, for each copy of the minor allele, 
respectively. Notably, the minor allele of the IGAP “hit” rs9381040 is associated with both 
decreased AD-risk and increased TREML1 and TREM2 levels.” 
 
Page 10, 2nd paragraph, 4th sentence was added as follows: “…the minor allele of rs9357347 
associates with reduced AD-risk (OR=0.95, 95% CI=0.91-0.98, p=0.001) and increased 
TREML1 and TREM2 expression in the temporal cortex (p=0.0063, beta=0.088 and p=0.046, 
beta=0.090, respectively) (Table 2 and Fig. S2). These beta coefficients can be interpreted as an 
estimated 1.06-fold change of both TREML1 and TREM2, per rs9357347 minor allele, in this 
temporal cortex dataset.” 
 
Table 2: The beta coefficients shown for the IGAP AD-risk meta-analysis reflected effect size of 
the allele for AD risk association. These have now been replaced with odds ratios and 95% 
confidence intervals for easier interpretation of these results. The beta coefficients for the brain 
gene expression associations are retained for consistency with the text but described in the Table 
2 and 3 legends as below. 
 
Table 2 legend: “Given that the eGWAS expression measures were on a log2 scale, fold-change 
for the Mayo eGWAS beta coefficients = 2beta.” 
 
Table 3 legend: “Since in all three datasets the expression measures analyzed were on a log2 
scale, fold-change for the beta coefficients = 2beta.” 
 
Supplementary Material, Table S5, legend: “Z scores of the cognitive scores were analyzed, thus 
these beta coefficients can be interpreted as changes in z-score associated with each copy of the 
minor allele.” 
 
We have also added the following text to the Discussion section on page 15, 4th paragraph: 
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“While the fold change estimates in gene expression associated with rs9357347-C are modest at 
6-7%, the biological impact of the increase attributed to each copy of the minor allele, can be 
significant and may provide sufficient protection from disease in some individuals, particularly 
when considered over a lifetime. Furthermore, these estimates are based on RNA isolated from 
tissue samples and not microglial cells where both TREM2 and TREML1 are predominantly 
expressed [35], and where expression levels of these genes may be impacted to a greater extent 
by regulatory variants. Additional studies will be needed to determine the impact of such 
expression changes on the biology of microglial cell function.” 
 
Comment 13: 
“13.      The  OR  presented  in  first  line  of  Page  9  does  not  correspond  to  a  risk  statement.  Is  the  OR 
conditional or marginal?” 
 
In this line the OR pertains to the test of association of rs9357347 with the diagnosis of AD in 
the IGAP stage 1 study, which was a meta-analysis of the four largest AD case-control GWAS. 
This study is mentioned in the Introduction in the former and current versions of our manuscript 
(page 4, 3rd paragraph, 2nd sentence). To clarify the sentence queried by our Reviewer, we 
modified it as follows (page 10, 2nd paragraph, 3rd sentence): 
 
“As expected, the minor allele of rs9357347 is associated with reduced AD-risk (OR=0.95, 95% 
CI=0.91-0.98, p=0.001) in the IGAP meta-analysis [12] and with increased TREML1 and 
TREM2 expression in the temporal cortex in the Mayo Clinic WG-DASL eQTL analysis 
(p=0.0063, beta=0.088 and p=0.046, beta=0.090, respectively) (Table 2 and Fig. S2).” 
 
Comment 14: 
“14.    For the sake of clarity, can the authors provide a better explanation for the high regulome scores 
of some variants in their study?” 
 
We now include the following text on page 6, in the Materials and Methods, section 2.1:  
 
“Variants were further prioritized by their Regulome score. Regulome scores were obtained from 
the Regulome database, which annotates variants with regulatory information from 962 different 
datasets and a variety of sources, including ENCODE [16]. Regulome scores are on a scale from 
1 to 6, and these numerical categories are sub-classified with letters based on the number of lines 
of evidence of functional consequence. A value of 1a is assigned to the variant with the most 
evidence of regulatory potential, while a score of 6 has the least [16].” 
 
 
Comment 15: 
“15.    Page 10 Paragraph 3. Did the authors perform a conditional analysis to examine the association of 
rs9357347  after  conditioning  on  rs6916710?  Was  the  signal  partially  explained  by  the  correlated 
variant? If so, can it provide any additional mechanistic understanding?” 
 
As stated on that paragraph, rs6916710 did not show evidence of association with either AD-risk 
or gene expression; therefore, conditional analyses were not performed with this variant. To 
address our Reviewer’s comment, we have now performed this analysis. The table below shows 
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results for the test of association of rs9357347 with temporal cortex TREML1 and TREM2 levels, 
both with and without conditioning on rs6916710. In addition, we show the results obtained 
when we tested the association of rs6916710 with these genes’ levels, both with and without 
conditioning on rs9357347. 
 
As shown here, the p-values for the association of rs9357347 with both TREML1 and TREM2 
levels become larger upon conditioning on rs6916710, although the association remains 
significant at p=0.02. Rs6916710 does not have significant association with either TREML1 and 
TREM2 levels, as already stated above and in the manuscript. The association of rs6916710 with 
levels of these genes remains non-significant, with  p-values that become larger upon 
conditioning on rs9357347.  
 
While conditioning the test of association of rs9357347 on rs6916710 leads to larger p-values for 
the former, given the lack of any gene expression or AD-risk association with rs6916710, and 
lack of evidence of its regulatory potential, rs6916710 is unlikely to be accounting for part of the 
association of rs9357347 with expression due to a mechanistic, biological effect. Rather, it is 
possible that there are additional functional, regulatory variants in the same LD block as 
rs9357347, which could in part be accounting for the associations with expression observed with 
rs9357347. Rs6916710 may be a marker for such additional functional, regulatory variants.  
 
We added a sentence to the Discussion section, page 17, 3rd paragraph, 2nd sentence, to highlight 
the possibility of additional functional, regulatory variants in the same LD block as rs9357347: 
 
“We identified rs9357347 as a putative regulatory variant that is associated with protection from 
AD and with increased TREML1 and TREM2 brain levels, and nominate rs9357347 as one of the 
functional variants that accounts for the IGAP AD-risk signal. Additional studies are needed to 
validate the function of this variant, and to explore the possibility of the presence of other 
variants at this locus that could contribute to associations observed with rs9357347.” 
 
Given the complexities discussed above and the lack of further mechanistic insight gained from 
the analyses we show below, we opted not to include the conditional analyses with rs6916710 in 
the manuscript, however, we can do so, if our Reviewer feels that we should. 
         
 
 Rs9357347 temporal cortex gene expression association without conditioning on rs6916710 
Gene beta p-value 
TREML1 0.088 6.28E-03 
TREM2 0.090 4.61E-02 
 Rs9357347 temporal cortex gene expression association conditioning on rs6916710 
Gene beta p-value 
TREML1 0.120 2.09E-02 
TREM2 0.058 4.36E-01 
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 Rs6916710 temporal cortex gene expression association without conditioning on rs9357347 
Gene beta p-value 
TREML1 0.054 7.70E-02 
TREM2 0.072 9.20E-02 
 Rs6916710 temporal cortex gene expression association conditioning on rs9357347 
Gene beta p-value 
TREML1 -0.040 4.53E-01 
TREM2 0.040 6.15E-01 
 
 
Comment 16: 
“16.      Can the authors provide an explanation as to why their findings did not replicate  in either of the 
replication cohorts? Does age play a role in any of these expressions? ” 
 
In the course of the revision of our manuscript, we noticed that, unlike for the other two cohorts, 
the gene expression values from the ROS/MAP RNAseq dataset were not log2 transformed as 
they should have been. We repeated the analyses for ROS/MAP using the log2 transformed-
FPKM gene expression values. We also repeated the meta-analyses. As shown in the updated 
Table 3 and below, rs9357347 is associated with TREM2 levels in both the Mayo Clinic WG-
DASL and ROS/MAP cohorts, although a significant association with TREML1 is observed only 
in the former. We discuss this point further in our response to Reviewer #2, Comment #2. Please 
also see our response to Reviewer #5, Comment #4. 
 
To look into the influence of age on expression levels we performed additional analyses and 
included these results as outlined in our response to Comment #8 by our first Reviewer. 
 
Table 3. Meta-analysis of rs9357347 eQTL results from three independent datasets.  
Dataset Sample size MAF 
TREML1  TREM2 
beta SE p  beta SE p 
Mayo WG-DASL 380 0.307 0.088 0.032 6.28E-03  0.090 0.045 4.61E-02
Mayo Clinic RNAseq 132 0.311 -0.030 0.108 7.82E-01  0.084 0.128 5.13E-01
ROS/MAP RNAseq 494 0.281 0.089 0.114 4.36E-01  0.124 0.060 3.77E-02
Meta-analysis 1006   +-+   3.36E-02  +++   3.54E-03
Meta-analysis of rs9357347 eQTL results from temporal cortex (Mayo WG-DASL and Mayo 
Clinic RNAseq) and dorsolateral prefrontal cortex samples (ROS/MAP). MAF = minor allele 
frequency. SE = standard error. Since in all three datasets the expression measures analyzed were 
on a log2 scale, fold-change for the beta coefficients = 2beta. The meta-analysis was performed 
using METAL, with weighted average of z-scores from the individual study p-values, weighted 
according their sample size. 
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Minor Comment 1: 
“1.    In certain places "that" might be more appropriate than "which." ” 
 
The word “which” has been edited when appropriate, as follows: 
 
Page 4, last paragraph, 2nd sentence: This sentence was simplified, and the phrase starting with 
the word “which” was deleted: “TREML2 p.S144G is in tight LD with the intergenic variant, 
rs9381040, that demonstrated the most significant association at the TREM locus in the IGAP 
AD-risk GWAS meta-analysis (p=6x10-04) [12]. 
 
Page 14, 1st paragraph, 1st sentence: This sentence was simplified, and the word “which” was 
deleted:“The minor allele of this variant is associated with both decreased AD-risk and with 
increased TREML1 and TREM2 brain expression in the temporal cortex.” 
 
 
Minor Comment 2: 
“2.    Some sentences are too long and harder to follow. A little simplification might help.” 
 
In addition to the sentences shown in the response above, we have also simplified the following 
sentences: 
 
Page 7, 2nd paragraph, 1st sentence: “Temporal cortex RNAseq data from two RNAseq cohorts: 
“Mayo Clinic RNASeq” and “ROS/MAP RNAseq” were employed for replication of the 
associations that were detected with the WG-DASL gene expression measurements. The Mayo 
Clinic RNASeq dataset is comprised of 84 LOAD and 48 non-AD brains from the Mayo Clinic 
Brain Bank that were not part of the Mayo Clinic WG-DASL cohort but whose 
neuropathological diagnosis followed the same criteria. The ROS/MAP RNAseq dataset is 
comprised of RNAseq data from 288 AD and 206 non-AD samples that are part of the 
ROS/MAP cohort (Table 1) previously described [18, 19].” 
 
Page 10, 2nd paragraph, 6th sentence:  
“Unlike the IGAP “hit” (rs9381040), rs9357347 lies within sequence subject to histone 
modifications and within a DNAse hypersensitive site detected by the Roadmap Epigenomics 
Consortium [22] in brain regions relevant to AD pathology such as the hippocampus. 
Furthermore, this variant is predicted to affect transcription factor binding (SP1 and PPAR) as 
catalogued in HaploReg (http://www.broadinstitute.org/mammals/haploreg/haploreg.php) [23].” 
 
Page 13, 2nd paragraph, 3rd sentence: “Whereas TREML1 is expressed in both cerebellum and 
temporal cortex of all subjects, TREM2 is expressed in 98% of temporal cortex and 41% of 
cerebellum samples.” 
 
Page 15, 2nd paragraph, 4th sentence: “Interestingly, rs9357347 is predicted to affect transcription 
factor binding (SP1 and PPAR) as catalogued in HaploReg. These two transcription factors are 
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known be important in regulating key players in the inflammatory response and lipid metabolism 
[33, 34].” 
 
Page 16, 2nd paragraph, 4th sentence: “Further, TREML2 expression is too low to be reliably 
measured in brain tissue (TCX and CER). This raises the possibility that the association with 
TREML2 p.S144G is due to its LD with a functional variant(s) that influences the function or 
level of a nearby TREM gene(s), such as TREML1 or TREM2.” 
 
Page 17, 3rd paragraph, 1st sentence: “In summary, we characterized expression of TREM genes 
in cerebellum and temporal cortex and determined TREML1 and TREM2 to be the only reliably 
expressed TREM genes in these brain regions. We identified rs9357347 as a putative regulatory 
variant that associates with protection from AD and with increased TREML1 and TREM2 brain 
levels, and nominate rs9357347 as one of the functional variants that accounts for the IGAP AD-
risk signal.” 
 
 
Minor Comment 3: 
“3.    Page 5, Paragraph 2, Line 10, missing a reference for "… reported …".”  
 
We have added the references to this sentence on page 5, 2nd paragraph, as shown below: 
 
“Some variants at the TREM locus have been reported to associate with AD endophenotypes [11, 
13, 14].” 
 
 
Minor Comment 4: 
“4.    Page 5, Line 25, "associated" instead of "associate".”  
 
This word has been replaced as suggested (now on page 5, line 80). 
 
 
Minor Comment 5: 
“5.      Page  6,  continuation  of  paragraph  from  Page  5.  You  are  already  making  a  conclusion  in  the 
introduction. I'd suggest that you remove the last line.”  
 
We have deleted this sentence. 
 
 
Minor Comment 6: 
“6.    Page 8 last line replace "associates" with "is associated".”  
 
This word, now on page 10, 2nd paragraph, line 195, has been replaced, as suggested. 
 
 
 
Reviewer #2: 
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“The  manuscript  entitled  "A  regulatory  variant  at  the  TREM  gene  cluster  associates  with  decreased 
Alzheimer's disease risk, and increased TREML1 and TREM2 brain gene expression" by Carrasquillo et al. 
describes  an  association  study  between  TREM2  SNPs  and  brain  expression  levels  of  genes  positioned 
within the TREM cluster. The expression association analysis was well designed and thoroughly executed. 
The  study  includes appropriate  replication cohorts.   The  study contributes  to  the understanding of  the 
broader role of TREM  locus  in AD, beyond the rare coding mutations; the results are of  interest to  the 
community of investigators studying the genetic of LOAD.” 
 
We thank this Reviewer for their favorable comments. 
  
“However,  based  on  the  results  presented  in  this  manuscript  the  authors  cannot  rule  out  the  high 
possibility  that  other  genetic  variants,  including  structural  variants  that  are  in  high  LD  with  SNP 
rs9357347, are responsible for the observed statistical associations with TREM2 and TREM1L expression. 
There are several major concerns and revisions are needed accordingly:” 
 
Comment 1: 
“1)  The  conclusion  should  be  phrased  more  carefully.  The  results  reported  in  this  work  suggest 
associations,  however,  the  actual  variants  underlying  the  observed  associations  remained  to  be 
determined. This will require experiments using appropriate biological systems,  in which  the candidate 
variant is the only different site. 
 
The title should be revised as well accordingly for accuracy; at this stage SNP rs9357347  is a candidate 
regulatory variant.” 
 
We fully agree with this reviewer’s comment. As suggested, the word “candidate” has been 
added to the title of the manuscript.  
 
In addition, we added a paragraph (Discussion, page 15, last paragraph) to emphasize the need 
for experiments in appropriate systems as follows: 
 
“While the fold change estimates in gene expression associated with rs9357347-C are 
modest at 6-7%, the biological impact of the increase attributed to each copy of the minor allele, 
can be significant and may provide sufficient protection from disease in some individuals, 
particularly when considered over a lifetime. Furthermore, these estimates are based on RNA 
isolated from tissue samples and not microglial cells where both TREM2 and TREML1 are 
predominantly expressed [35], and where expression levels of these genes may be impacted to a 
greater extent by regulatory variants. Additional studies will be needed to determine the impact 
of such expression changes on the biology of microglial cell function.” 
We have also provided additional language in the discussion section (page 17, 3rd paragraph, 
penultimate sentence): 
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“Additional studies are needed to validate the function of this variant, and to explore the 
possibility of the presence of other variants at this locus that could contribute to associations 
observed with rs9357347.”   
 
We note that our original manuscript had already raised these possibilities in the Discussion 
(please see the un-highlighted text in the paragraph shown under Comment #2 below). However, 
our additions in response to Comment #1 further enhance the cautionary language. 
 
Comment 2: 
“2) It is likely that SNP rs9357347 and the other 3 SNPs in LD block 2 tag the actual regulatory variant/s 
//haplotype. Deep sequencing analysis targeted for block 2 (specifically the region that overlaps with the 
Roadmap Epigenomics signals) is necessary to identify the actual risk/protective variant.” 
 
We are also in complete agreement with this assessment, and now propose this approach 
specifically in the discussion section (page 17, 1st paragraph, penultimate sentence), as shown 
below: 
 
“Both rs9357347 and p.S144G should be tested for their functional potential and influence on 
outcomes of inflammation and neuroprotection. It remains possible that rs9357347 is in LD with 
an untested true functional variant with effects on transcription and AD-risk. It is likewise 
possible that while rs9357347 is associated with both AD-risk and gene expression levels, these 
joint effects are coincidental due to LD, rather than being related. These possibilities need to be 
explored through sequencing of the entire TREM locus, or via targeted sequencing of LD block 2 
where rs9357347 resides. Thus, our findings provide a testable hypothesis for a strong candidate 
functional variant, specific transcription factors and their effects on TREML1 and TREM2 
levels.” 
 
 
Comment 3: 
“3) The authors should present the mRNA expression  levels of TREM2 and TREM1L stratified by disease 
status using  the  study's  cohorts.  This will be also helpful  to determine  the direction of  the  change  in 
expression in AD vs. control.” 
 
We are thankful for this suggestion. We now include box plots of TREML1 and TREM2 gene 
expression levels stratified by diagnosis for each of the 3 datasets in Fig. S5. The trends observed 
in these box plots are described in the Supplementary Material (page 9, 3rd paragraph) as shown 
below: 
 
“Association of diagnosis with TREML1 and TREM2 expression  
To assess if diagnosis is associated with TREML1 and/or TREM2 gene expression levels, linear 
regression analyses were performed in R in each of the three datasets, adjusting for all other 
covariates included in the eQTL analyses described in the Materials and Methods section 2.4, as 
well as rs9357347 minor allele dose. The box plots in Fig. S5 show the direction of the change in 
expression between AD and nonAD subjects, and indicate the significance of the association for 
each test. We observe a consistent trend of higher TREML1 and TREM2 expression in AD versus 
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nonADs, although some of these associations do not reach statistical significance. The trend 
toward higher TREML1 and TREM2 expression in AD subjects could be a reflection of 
microglial activation and/or proliferation known to occur in AD brains.”   
 
Fig. S5. Box plots of gene expression residuals for TREML1 and TREM2 in AD and nonAD 
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subjects, for each of the three cohorts investigated. 
 
A and B: Expression measure residuals for TREML1 (A) and TREM2 (B) in the Mayo WG-
DASL dataset, adjusted for rs9357347 minor allele dose, age-at-death, sex, APOE 4 dose, RIN, 
(RIN-RINmean)2 and PCR plate. TREML1 (C) and TREM2 (D) in the Mayo Clinic RNAseq 
dataset, adjusted for rs9357347 minor allele dose, age-at-death, sex, APOE 4 dose, RIN, (RIN-
RINmean)2 and flowcell. TREML1 (E) and TREM2 (F) in the ROS/MAP RNAseq dataset, 
adjusted for rs9357347 minor allele dose, age-at-death, sex, APOE 4 dose, RIN, (RIN-
RINmean)2. 
 
 
 
Comment 4: 
“4)  A  description  of  the  statistical  analyses  has  to  be  included  in  the  method  section  of  the  main 
manuscript  (not  the  supplementary  material).  The  results  section  relies  completely  on  the  statistical 
methods.” 
 
A description of the statistical analyses is now included in the Material and Methods, section 2.4, 
of the main manuscript on page 7, 3rd paragraph. 
 
“2.4. Statistical Analysis 
Normalized transcript expression levels, on a log2 scale, were tested for associations with 
TREM locus genotypes in each of the three datasets (Mayo WG-DASL, Mayo Clinic RNAseq 
and ROS/MAP RNAseq) via multivariable linear regression analyses implemented in PLINK 
[20]. An additive model was applied adjusting for age-at-death, sex, diagnosis, RNA Integrity 
Number (RIN) and adjusted RIN squared (RIN-RINmean)2 in all expression analyses, and APOE 
4 dosage and PCR plate in Mayo WG-DASL only, and flowcell in the Mayo Clinic RNAseq 
dataset only. The eQTL analysis in the discovery, WG-DASL dataset, included APOE 4 dose as 
a covariate given the strong effect of this allele on AD. However, since a significant association 
was not detected with this covariate in the rs9357347 eQTL analyses in the discovery set, APOE 
4 dose was not included in the eQTL analyses implemented on the replication cohorts. For 
comparison, we have performed the eQTL analyses in all three datasets with and without 
adjustment for APOE 4 dose and do not observe a substantial difference in the association 
results between these two models. 
Meta-analyses were performed on eQTL results from the three independent datasets. For 
these analyses, METAL [21] was implemented using weighted average of z-scores from the 
individual study p-values, weighted according their sample size.” 
 
 
Comment 5: 
“5) Corrections for multiple tests should be applied for the nominal p values. (different tissues, several LD 
blocks, 2 genes).” 
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Correction for multiple tests was not applied to the eQTL results from the Mayo WG-DASL 
since this was our discovery cohort from which variants with eQTL p-values <0.05 and evidence 
of AD risk association were selected and further prioritized based on annotation of regulatory 
potential. Since only one variant, rs9357347, fulfilled these criteria, only this variant was 
evaluated in the replication eQTL cohorts. We have clarified the variant selection process by 
adding text to page 6, 2nd paragraph, as shown below. We also added, on page 7, the terms 
“Discovery eQTL cohort” and “Replication eQTL cohorts”, following “Mayo Clinic Whole 
Genome-DASL dataset” and “RNAseq datasets” subtitles in the Methods section, respectively.   
 
“We restricted our analysis to variants located within 100kb of any coding TREM family 
gene at the chromosome 6p21.1 TREM gene cluster (Fig. 1). Variants were further selected 
based on the statistical significance of their AD-risk association in the IGAP stage 1 meta-
analysis [12] (Supplementary Methods), where only those variants with p-values  0.0015 were 
kept. This p-value cut-off was arbitrarily chosen to select those variants that existed in both the 
IGAP stage 1 AD GWAS and our discovery eQTL cohort, Mayo Clinic Whole Genome-DASL 
dataset, and that could be genotyped, if needed, in the replication eQTL cohorts, using cost-
effective medium-throughput assays. Variants were further prioritized by their Regulome score. 
Regulome scores were obtained from the Regulome database, which annotates variants with 
regulatory information from 962 different datasets and a variety of sources, including ENCODE 
[16]. Regulome scores are on a scale from 1 to 6, and these numerical categories are sub-
classified with letters based on the number of lines of evidence of functional consequence. A 
value of 1a is assigned to the variant with the most evidence of regulatory potential, while a 
score of 6 has the least [16].” 
 
Comment 6: 
“6)  rs9357347 demonstrated only  suggestive association  in  the  replication cohort  that has no overlap 
with the discovery cohort.”  
 
As also discussed in our response to Reviewer #1, Comment #16, in the course of the revision of 
our manuscript, we noticed that, unlike for the other two cohorts, the gene expression values 
from the ROS/MAP RNAseq dataset were not log2 transformed as they should have been. We 
repeated the analyses for ROS/MAP using the log2 transformed-FPKM gene expression values. 
We also repeated the meta-analyses. As shown in the updated Table 3, rs9357347 associates 
with TREM2 levels in both the Mayo Clinic WG-DASL and ROS/MAP cohorts, although a 
significant association with TREML1 is observed only in the former.  
 
Although the association with TREML1 does not reach significance in ROS/MAP, the beta 
coefficient overlaps with that in the WG-DASL cohort (Table 3). The lack of significant 
association in the Mayo RNAseq cohort is likely due to its relatively small size; yet in this cohort 
the effect size detected for TREM2 is very similar to that in the WG-DASL cohort, as evidenced 
by the improved significance of the association with TREM2 levels upon meta-analysis, as 
compared to this association in the discovery, WG-DASL cohort. 
 
Please also see our response to Comment #8 by Reviewer #1, Comment#4 by Reviewer #5. 
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Reviewer #4: 
“This  paper  describes  the  identification  of  an  intergenic  variant  (rs9357347)  as  a  causative  factor  in 
expression  regulation  of  transcripts  TREM2  and  TREML1.  The  functional  variant  was  previously 
associated with reduced risk of Alzheimer disease within the IGAP AD‐risk GWAS meta‐analysis published 
by  Lambert  et  al  (2013).  The  authors  argue  that  the  identified  variant  underlies  the  genome‐wide 
association signal within the TREM locus. Overall, the paper is well written. Methodology and results are 
well structured. The identification of several putative eQTL variants and selection of the putative causal 
variant are described in detail.” 
 
We thank this Reviewer for their favorable comments.   
 
 
“A drawback is the absence of significant expression regulation by this variant in the replication datasets, 
which should be addressed in more detail.” 
  
Please see the response to Reviewer #1 Comments #8 and #16; Reviewer #2 Comment #6 and 
Reviewer #5, Comment #4. 
 
 
“Second,  absence  of  expression  data  for  five  out  of  seven  genes  within  the  TREM  locus  limits  the 
interpretation of the  identified variants as the true functional factor explaining the GWAS signal at this 
locus.” 
 
Please see the response to Comment #2 below. 
 
 
Comment 1: 
“Main Comments: 
*      The evidence for the regulatory variant  'nominated'  in this paper  is more  limited than the text and 
title  lead  to  believe.  Association  of  rs9357347  with  increased  TREML1  and  TREM2  expression  levels 
reaches significance  in the Mayo WG‐DASL discovery dataset only. Given that associations fail to reach 
statistical significance in both the Mayo Clinic RNAseq and ROS/MAP RNAseq datasets, the meta‐analysis 
association  is  driven  by  the  Mayo  WG‐DASL  only.  Furthermore,  the  direction  of  effect  in  TREML1 
expression  is  not  equal  among  the  datasets.  Since  TREML1  and  TREM2  expression  levels  from  the 
microarray could be correlated to expression  levels  in a 93 AD patient dataset (results; page 7;  line 37‐
47, and  figure S1) why would  the association of rs9357347 with TREML1 and TREM2 expression  levels 
remain specific to the microarray data? Please tone down and discuss.” 
 
We address the replication comment in our responses to Reviewer #1, Comment #16; Reviewer 
#2, Comments #2, and #6. 
 
We discuss differences in the ages of the cohorts as a potential source of lack of replication in 
our response to Reviewer #1, Comment #8. 
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We address the toning down of the Discussion in our responses to Reviewer #2, Comments #1 
and #2. 
 
 
 
Comment 2: 
“*    Strongest association signal from the IGAP meta‐analysis is found near the TREML2 gene.  Analysis 
of TREML2 gene expression was excluded due failure to detect expression  levels. Do the authors expect 
that  TREML2  expression  regulation  would  be  relevant  to  the  protective  effects  of  TREM  locus  eQTL 
variants? Do  the  authors  expect  any  eQTL  effect  of  rs9357347  on  TREML2  or  additional  TREM  locus 
transcripts?” 
 
Table S1 now includes the percent detection of each of the five TREM coding genes, in each of 
the three expression datasets evaluated in this study. These data demonstrate the low percentage 
of subjects with detectable levels of TREML2 across all 3 cohorts.  
 
23 
Carrasquillo et al. ADJ-D-16-00130 
 
Table S1. Percent detection of TREM locus transcripts. 
         Mayo WG‐DASL: Cerebelluma 
Mayo WG‐DASL:       
Temporal Cortexb 
 Mayo Clinic 
RNAseq: Temporal 
Cortexc 
ROS/MAP RNAseq: 
DFPCd 
Symbol  Ensembl Gene ID  WG‐DASL Probe ID 
AD +   
non‐
AD 
AD  nonAD 
AD +   
non‐
AD 
AD  Non‐AD  AD + non‐AD  AD + non‐AD 
TREM1  ENSG00000124731  ILMN_1688231  0.00  0.00  0.00  0.25  0.00  0.51  18.18  66.99 
TREML1  ENSG00000161911  ILMN_1690783  100.00  100.00  100.00  100.00  100.00  100.00  100.00  97.84 
TREM2  ENSG00000095970  ILMN_1701248  40.91  43.59  37.29  98.25  99.50  96.95  100.00  100.00 
TREML2  ENSG00000112195  ILMN_1740864  17.38  17.44  17.51  6.27  10.40  2.03  8.33  24.75 
TREML4  ENSG00000188056  ILMN_2205322  6.15  4.62  7.91  2.26  2.97  1.52  2.27  15.13 
 
The percentage of samples with detectable expression of TREM family transcripts in each of the expression datasets studied. For the 
WG-DASL dataset (a,b) the corresponding WG-DASL probe is indicated. Only TREML1 and TREM2 expression are detectable above 
background in at least 50% of the Mayo WG-DASL samples tested (a,b), in at least one tissue; c: A detection threshold >-1, for cqn 
normalized expression levels was used to determine percent detection; d: percent detection was calculated as the proportion of subjects 
who express > 0 FPKM, DFPC = dorsolateral prefrontal cortex. 
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Genes that are lowly expressed, or not expressed in the brain are unlikely to directly impact the 
pathophysiology of AD. However, it is indeed possible that their expression in the periphery 
could affect the disease process, as had been stated in the discussion (page 16, 2nd paragraph, 
penultimate sentence) and shown below: 
 
“Alternatively, the protective effect of p.S144G could be mediated directly through the function 
of TREML2 in a cell with abundant expression, such as macrophages, in which TREML2 is 
known to be upregulated in response to inflammation, [36].” 
We now add (page 16, 2nd paragraph, last sentence) that: “It is also possible that significant 
rs9357347 eQTL associations would be detected with TREML2 or other TREM locus transcripts 
in tissues where these genes are more abundantly expressed.” 
Also, it is important to acknowledge that moderate levels of expression in specific central 
nervous system cell types, may not be detectable in tissue samples composed of a heterogenous 
set of cell types, such as brain tissue used in our study. We now raise this point in the discussion 
section, page 16, 1st paragraph, last two sentences.   
 
“Furthermore, these estimates are based on RNA isolated from tissue samples and not 
microglial cells where both TREM2 and TREML1 are predominantly expressed [35], and where 
expression levels of these genes may be impacted to a greater extent by regulatory variants. 
Additional studies will be needed to determine the impact of such expression changes on the 
biology of microglial cell function.” 
 
 
Comment 3: 
“Lower bound cut‐off for inclusion of RNA was set at RIN>5. Regardless of the correction for RIN value 
that was employed in the eQTL analysis of rs9357347, could the authors identify any group differences 
in TREM2 and TREML1 expression regulation or detection percentage when clustering samples based on 
RIN values?” 
 
We have done additional analyses, which we depict in a new Figure (Fig. S6) and in a new Table 
(Table S3). In summary, RIN does not significantly impact the results of the eQTL analyses. We 
added the following new text to Supplementary Material, page 7, last paragraph. 
 
“Effect of RIN on percent detection and rs9357347 eQTL association  
Fig. S6 shows TREML1 and TREM2 detection percentage stratified by RIN, and demonstrates 
that neither TREML1 nor TREM2 detection percentage is affected by RIN. Table S3 shows 
results of the rs9357347 eQTL associations in the Mayo WG-DASL dataset when stratifying by 
samples above and below the median RIN of 6.5 (Table S3). These results indicate that RIN 
does not significantly impact the magnitude of the rs9357347 eQTL associations, as the 
estimates of the beta coefficients overlap with those observed in the analysis not stratified by 
RIN (Table S2). Although the significance of the association is lessened in the stratified 
analysis, this is likely due to the smaller sample size of the stratified groups compared to the 
sample size of the combined analysis.” 
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Table S3. Association of the TREM locus candidate regulatory variant, rs9357347, with 
TREML1 and TREM2 gene expression stratified by RIN. 
Gene 
Symbol  RIN group  N  beta  SE  p‐value  
TREML1  RIN < 6.5  188  0.087  0.042  0.043 
RIN > 6.5  192  0.084  0.046  0.069 
TREM2  RIN < 6.5  188  0.110  0.063  0.084 
RIN > 6.5  192  0.075  0.065  0.250 
 
Data shown for Mayo WG-DASL temporal cortex (AD+Non-AD) dataset. Samples were 
stratified into two groups representing those with a RIN below the median RIN of 6.5 and those 
with a RIN above 6.5. N = sample size. SE= standard error. Given that all expression measures 
were on a log2 scale, fold-change for the beta coefficients = 2beta. 
 
 
Fig. S6. Bar charts of percentage of subjects with detectable gene expression for TREML1 
and TREM2 across groups of subjects defined by RIN value. 
 
Subjects were binned according to RIN value and the proportion of subjects in each bin that met 
the detection threshold was calculated. A and B: Expression detection percentage for each RIN 
bin for TREML1 (A) and TREM2 (B) in the Mayo WG-DASL dataset. C and D:  Expression 
detection percentage for each RIN bin for TREML1 (A) and TREM2 (B) in the Mayo Clinic 
RNAseq dataset.  E and F:  Expression detection percentage for each RIN bin for TREML1 (A) 
and TREM2 (B) in the ROS/MAP RNASseq dataset. 
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Minor Comment 1: 
“Please report RNA concentrations submitted for sequencing.” 
 
These concentrations are now indicated as shown below: 
 
 Supplementary Material, page 4, 2nd paragraph, 3rd sentence for the Mayo RNAseq: “Samples 
were randomized prior to the transfer of 40 (TCX) or 50 (CER) ng/ul of RNA to the Mayo Clinic 
Medical Genome Facility Gene Expression and Sequencing Cores for library preparation and 
sequencing.”  
 
Supplementary Material, page 5, 3rd paragraph, 3rd sentence for the ROS/MAP RNAseq: “Only 
samples with a RIN score >5 were used for library construction, which was assembled using 
50ng/ul of RNA for the strand-specific dUTP method.” 
  
 
Minor Comment 2: 
“*    Detection percentage for TREM locus transcripts is provided for the Illumina WGS‐DASL microarray 
dataset only. Please provide the detection percentages for all seven TREM locus transcripts in both the 
discovery and replication datasets.” 
 
Table S1 now includes the percent detection of each of the five TREM coding genes, in each of 
the three expression datasets evaluated in this study. The WG-DASL array lacked probes for the 
two TREM pseudogenes; therefore they were not measured in the Mayo WG-DASL cohort. 
Expression levels were not available for the TREM pseudogenes in the ROS/MAP dataset. Based 
on the Mayo RNAseq dataset, the percent detection of TREML3P and TREML5P in temporal 
cortex are 15% and 5% respectively. This information is now included in the legend of Table S1. 
 
Please also see responses to Main Comment #2 by Reviewer #4. 
 
 
Minor Comment 3: 
“*      Interpretation  of  pairwise  LD  between  rare  and  common  variants  is  difficult  due  to  frequency 
inequalities.  Conclusions  on  LD  blocks  (e.g.  page  9,  last  paragraph)  should  be  presented  with  more 
caution.” 
 
We note that the LD blocks and pairwise disequilibrium were assessed in our study using both 
D’ and r2.  D’ provides a more accurate assessment of LD between variants that have different 
allele frequencies than r2, as D’ is a relative measure of LD based of the maximum 
disequilibrium attainable given the allele frequencies. The use of both LD measures is stated 
throughout the manuscript and in Figure 3 (relevant section of legend pasted below). 
 
“Fig. 3. LD Plot of TREM locus variants. 
LD plot of TREM locus variants where haplotype blocks were determined with the solid spine 
definition; square colors correspond to D’ (tight LD=warmer colors, weak LD=cooler colors) 
and r2 values are shown within the squares (Supplementary Methods).”   
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Minor Comment 4: 
“*    Figures 1, 2 and 3 are a little rough and premature; the authors might reshape these figures to aid 
interpretation of gene and variant positions.” 
 
Please note that all figures were submitted as high resolution images, all of which are of high 
quality and can be downloaded by clicking on the link provided on the merged pdf of the 
manuscript documents. If there are specific suggestions regarding how these can be improved 
further, we will be happy to apply these. 
 
Minor Comment 5: 
*      Exclusion of missense  variant TREML2 p.S144G as a  functional  factor  is motivated by  the  variant 
being  labeled  'benign'  in  the  PolyPhen2  prediction  software.  This  conclusion  might  be  too  strong, 
especially since TREML2 expressions levels could not be evaluated. 
We recognize that functional prediction algorithms like PolyPhen are fallible, and acknowledge 
that TREML2 p.S144G may be functional and could influence AD-risk, as indicated on page 16, 
2nd paragraph, last two sentences: 
“Alternatively, the protective effect of p.S144G could be mediated directly through the function 
of TREML2 in a cell with abundant expression, such as macrophages, in which TREML2 is 
known to be upregulated in response to inflammation, [36]. It is also possible that significant 
rs9357347 eQTL associations would be detected with TREML2 or other TREM locus transcripts 
in tissues were these genes are more abundantly expressed.” 
  
 
Reviewer #5: 
 
“Drs. Carrasquillo et.al. used both their own samples and data plus publically available RNA‐Seq data to 
elucidate  the  association  between  the  TREM  gene  cluster  and  AD  and  it's  pathologies,  primarily  by 
exploring gene expression in the TREM region.   They found that a protective variant in TREM2, shows a 
significant eQTL and  this association might be driving or at  least  contributing  to  the protective effect 
seen in the TREM region.” 
 
Overall nicely done analyses, just a couple comments:” 
 
We thank this reviewer for their positive comments. 
 
 
Comment 1: 
“(1) The authors should explain the Regulome Score, how  it  is calculated and how to  interpret  it.   I did 
not see that in either the main manuscript (methods or results) or supplementary.” 
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We now provide a description of Regulome scores, and explain how they are calculated and how 
to interpret them on page 6, in the Materials and Methods, section 2.1:  
 
“Variants were further prioritized by their Regulome score. Regulome scores were obtained from 
the Regulome database, which annotates variants with regulatory information from 962 different 
datasets and a variety of sources, including ENCODE [16]. Regulome scores are on a scale from 
1 to 6, and these numerical categories are sub-classified with letters based on the number of lines 
of evidence of functional consequence. A value of 1a is assigned to the variant with the most 
evidence of regulatory potential, while a score of 6 has the least [16].” 
 
 
 Comment 2: 
“(2) Since models used for the eQTL analyses should be mentioned in the main paper, specifically what 
covariates were adjusted  for.   This  is  important especially considering the differences  in  the 3 cohorts 
used for the meta‐analyses. And with respect to the adjustments, what was the rationale for adjusting 
for APOE status.  This should be explained.” 
 
A description of the statistical analyses is now included in the Material and Methods, section 2.4, 
of the Main Manuscript on page 7. Also, we now indicate the following in section 2.4: 
 
“The eQTL analysis in the discovery, WG-DASL dataset, included APOE 4 dose as a covariate 
given the strong effect of this allele on AD. However, since a significant association was not 
detected with this covariate in the rs9357347 eQTL analyses, APOE 4 dose was not included in 
the eQTL analyses implemented on the replication cohorts. For comparison, we have performed 
the eQTL analyses in all three datasets with and without adjustment for APOE 4 dose and do 
not observe a substantial difference in the estimates of the association between these two 
models.” 
 
Please also see our response to Reviewer #2, Comment #4. 
 
Comment 3: 
“(3) p=0.14 or p=0.11  is not  "suggestive association".   That  is quite a  stretch.   Just  focus on  the meta 
analysis results and direction” 
 
We have modified this sentence in light of the new results discussed in the response to comment 
#4 of this reviewer, and have replaced the phrase “suggestive association” on page 12, 4th 
paragraph, 2nd sentence, as shown below: 
 
“Although in  the ROS/MAP RNAseq dataset a significant association was only detected with 
the levels of TREM2 (Table 3), meta-analysis from the three independent study p-values (Mayo 
WG-DASL, Mayo RNAseq and ROS/MAP RNAseq) yielded significant results (TREML1 
p=3.4x10-2; TREM2 p=3.5x10-3), confirming the association of the rs9357347 minor allele with 
increased TREML1 and TREM2 gene expression.” 
 
Please also see our response to Reviewer #1, Comment #16 and Reviewer #2, Comment #6.  
 
Comment 4: 
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“Table 3:   It would be helpful to  include both MAF for each cohort/gene and also SE of the Betas.   The 
B=0.43  for  the ROSMAP TREM2  is a bit out of place.   The authors  should comment on what might be 
driving the very different beta (different from the other 2 cohorts).” 
 
We have added to Table 3 (also shown below) the MAF in each cohort and the SE of the beta 
coefficients. We are grateful for this reviewer’s comment regarding the larger beta reported for 
the ROS/MAP cohort. To address this concern, we plotted the expression values used as input 
for the linear regression analyses and realized that the input values for the ROS/MAP cohort had 
not been log2 transformed, but were rather the FPKM values. The ROS/MAP eQTL results 
presented now in Table 3 and elsewhere in the manuscript were re-generated using the log2 
transformed FPKM values. Upon this correction, the beta coefficients estimated in the 
ROS/MAP dataset overlap with the beta estimates in the discovery, WG-DASL cohort. In the 
corrected analysis of the ROS/MAP cohort, association of rs9357347 with TREM2 levels is 
significant. The pertinent text in the manuscript is modified accordingly. 
 
Please also see the response to Reviewer #1 Comments #8 and #16; Reviewer #2 Comment #6 
and Reviewer #4, Comment #1. 
 
Table 3. Meta-analysis of rs9357347 eQTL results from three independent datasets.  
Dataset Sample size MAF 
TREML1  TREM2 
beta SE p  beta SE p 
Mayo WG-DASL 380 0.307 0.088 0.032 6.28E-03  0.090 0.045 4.61E-02
Mayo Clinic RNAseq 132 0.311 -0.030 0.108 7.82E-01  0.084 0.128 5.13E-01
ROS/MAP RNAseq 494 0.281 0.089 0.114 4.36E-01  0.124 0.060 3.77E-02
Meta-analysis 1006   +-+   3.36E-02  +++   3.54E-03
Meta-analysis of rs9357347 eQTL results from temporal cortex (Mayo WG-DASL and Mayo 
Clinic RNAseq) and dorsolateral prefrontal cortex samples (ROS/MAP). MAF = minor allele 
frequency. SE = standard error. Since in all three datasets the expression measures analyzed were 
on a log2 scale, fold-change for the beta coefficients = 2beta. The meta-analysis was performed 
using METAL, with weighted average of z-scores from the individual study p-values, weighted 
according their sample size. 
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Abstract  32 
 33 
INTRODUCTION: We hypothesized that common Alzheimer’s disease (AD)-associated 34 
variants within the triggering receptor expressed on myeloid (TREM) gene cluster influence 35 
disease through gene expression. 36 
METHODS: Expression microarrays on temporal cortex and cerebellum from ~400 37 
neuropathologically diagnosed AD and non-AD subjects, and two independent RNAseq 38 
replication cohorts were used for expression quantitative trait locus (eQTL) analysis. 39 
RESULTS: TREML1 and TREM2 have reliably detectable expression. A variant within a DNase 40 
hypersensitive site 5’ of TREM2, rs9357347-C, associates with reduced AD-risk and increased 41 
TREML1 and TREM2 levels. Meta-analysis on eQTL results from three independent datasets 42 
(n=1,006) confirmed these associations (p=9.33.4x10-3 2 and 9.3x103.5x10-43, respectively). 43 
DISCUSSION: Our findings point to rs9357347 as a functional regulatory variant that 44 
contributes to a protective effect observed at the TREM locus in the International Genomics of 45 
Alzheimer’s Project (IGAP) GWAS meta-analysis, and suggest concomitant increase of 46 
TREML1 and TREM2 brain levels as a potential mechanism for protection from AD.  47 
 48 
 49 
 50 
Keywords: Alzheimer's disease, eQTL, TREM2, TREML1, regulatory variant  51 
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1. Introduction 52 
Whole genome and exome sequencing are used as complementary approaches to uncover 53 
novel loci that can be missed by GWAS, and enabled the discovery of strong, yet rare, missense 54 
coding AD-risk alleles within TREM2 that have a relatively large effect size on AD-risk  [1, 2]. 55 
TREM2 is a member of the triggering receptor expressed on myeloid (TREM) family, known to 56 
play a key role in modulating inflammation in the innate immune response [3]. This finding 57 
provided strong supportive evidence for the importance of inflammation in the etiology of AD, 58 
but the specific role played by TREM2 in AD pathophysiology remains unclear [4].   59 
Since the first two reports [1, 2], the risk effect of the most significant TREM2 rare 60 
missense variant p.R47H (a.k.a. rs75932628) has been replicated in multiple Caucasian series [5-61 
9], including a large meta-analysis of 24,086 AD cases and 148,993 controls [10]. TREM2 62 
resides within the TREM gene cluster on chromosome 6p21.1 (Fig. 1), which also includes the 63 
protein coding genes TREM1, TREML1, TREML2, TREML4 that could be additional plausible 64 
AD-risk genes. 65 
A missense variant in TREML2, p.S144G (a.k.a. rs3747742), that is not in linkage 66 
disequilibrium (LD) with TREM2 p.R47H, was reported to associate with reduced AD-risk [11]. 67 
TREML2 p.S144G is in strong tight LD with the TREM locus intergenic variant, rs9381040, that 68 
showed nominally significant AD association that demonstrated the most significant association 69 
at the TREM locus in the IGAP AD-risk GWAS meta-analysis (p=6x10-04) [12] and which was 70 
the strongest variant at this locus in the IGAP dataset [11]. The authors concluded that TREML2 71 
p.S144G is the functional variant that accounted for the IGAP TREM locus signal, althougheven 72 
though the significance of the AD-risk association with the intergenic rs9381040 is stronger 73 
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greater than that observed with for p.S144G. Further, TREML2 p.S144G does not have a 74 
predicted functional consequence (PolyPhen2 score=benign) or demonstrated functional 75 
outcome, suggesting that the IGAP signal at the TREM locus may be due to other functional 76 
variants.  77 
Some variants at the TREM locus have been reported to show associateion with AD 78 
endophenotypes [11, 13, 14]. Cerebrospinal fluid (CSF) levels of AD biomarkers, tau and ptau, 79 
associate with three variants at the TREM locus that are not in LD with each other: TREM2 80 
p.R47H (rs75932628), rs6916710 located in intron 2 of TREML2, and rs6922617 located 81 
downstream from NCR2 and outside the TREM cluster. Of these variants, only TREM2 p.R47H 82 
was associated with AD-risk [13]. More recently, a variant upstream of TREM2 (rs7759295) and 83 
a variant in intron 3 of TREM1 (rs6910730) were reported to be independently associated with 84 
increased AD pathology burden and increased rate of cognitive decline [14]. However, neither of 85 
these two variants shows association with AD-risk in the IGAP meta-analysis (p>0.05) [15]. 86 
Thus, it is possible that the effect observed with these variants on AD endophenotypes is due to 87 
their LD with an as yet defined functional variant(s) that influences AD-risk at the TREM locus. 88 
Thus, other than TREM2 p.R47H, none of the TREM locus variants previously reported to 89 
associate with AD endophenotypes show association with AD-risk. Functional AD- risk variants 90 
that influence AD endophenotypes are expected to show associatione both with these 91 
endophenotypes and risk of AD. Therefore, it is possible that these latter variants are not the 92 
functional variants per se, but merely markers of other un-tested functional variants.  93 
Collectively, these prior findings suggest that besides the TREM2 rare missense variants, 94 
there may be additional common variants at the TREM locus that influence AD-risk and/or its 95 
endophenotypes. We hypothesized that some of the common AD-risk variants at the TREM locus 96 
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confer disease risk via regulation of transcript levels of coding genes at the TREM gene cluster. 97 
In this study, we characterized the brain expression levels of the TREM family genes using 98 
microarray expression data; validated expression levels  by RNA sequencing (RNAseq); 99 
performed genetic associations with TREM locus genes reliably detected in cerebellum and 100 
temporal cortex with single nucleotide polymorphisms (SNP) that were also tested in the IGAP 101 
AD-risk GWAS meta-analysis; and annotated these variants for their effects on TREM gene 102 
expression levels and regulatory potential. Further, we obtained results for the top putative 103 
regulatory SNP from two other, independent cohorts with brain RNAseq data and performed 104 
meta-analysis of all three cohorts. Our findings suggest that the protective association at the 105 
TREM locus observed in the IGAP meta-analysis may be due, at least in part, to a common 106 
regulatory variant that influences brain levels of TREM2 and TREML1. 107 
 108 
2. Materials and Methods 109 
2.1 Variant selection 110 
We restricted our analysis to variants located within 100kb of any coding TREM family 111 
gene at the chromosome 6p21.1 TREM gene cluster (Fig. 1). Variants were further selected 112 
based on the strength statistical significance of their AD-risk association in the IGAP stage 1 113 
meta-analysis [12] (Supplementary Methods), where only those variants with p-values ≤ 114 
0.0015 were kept. This p-value cut-off was arbitrarily chosen to select those variants that existed 115 
in both the IGAP stage 1 AD GWAS and our discovery eQTL cohort, Mayo Clinic Whole 116 
Genome-DASL dataset, and that could be genotyped, if needed, in the replication eQTL cohorts, 117 
using cost-effective medium-throughput assays. Variants were further prioritized by their 118 
Regulome score. Regulome scores were obtained from the The regulatory potential of the tested 119 
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variants was assessed utilizing the Regulome database, which annotates variants with regulatory 120 
information from 962 different datasets and a variety of sources, including ENCODE [16]. 121 
Regulome scores are on a scale from 1 to 6, and these numerical categories are sub-classified 122 
with letters based on the number of lines of evidence of functional consequence. A value of 1a is 123 
assigned to the variant with the most evidence of regulatory potential, while a score of 6 has the 124 
least [16]..  125 
2.2 Mayo Clinic Whole Genome-DASL dataset (Discovery eQTL cohort) 126 
We utilized Illumina (Whole Genome-DASL=WG-DASL, Illumina, San Diego, CA) 127 
microarray gene expression data from our published human brain expression genome-wide 128 
association study (Mayo Clinic eGWAS) [17] conducted on brain tissue from autopsied AD 129 
patients (197 cerebellum, 202 temporal cortex) and non-AD subjects (177 cerebellum, 197 130 
temporal cortex) (Table 1). All AD subjects had neuropathologic diagnosis of definite AD [2]. 131 
The non-AD subjects did not fulfill neuropathologic criteria for definite AD, but many had other 132 
unrelated pathologies. Expression measures were generated as described previously [17]. A 133 
description of this cohort,  and generation of expression measures, and eQTL analysis is is 134 
provided in the Supplemetary Methods.  135 
2.3 RNAseq datasets (Replication eQTL cohorts) 136 
Temporal cortex RNAseq data from two RNAseq cohorts: “Mayo Clinic RNASeq” and 137 
“ROS/MAP RNAseq” were employed for replication of the associations that were detected with 138 
the WG-DASL gene expression measurements. The Mayo Clinic RNASeq dataset is comprised 139 
of 84 LOAD and 48 non-AD brains from the Mayo Clinic Brain Bank that were not part of the 140 
Mayo Clinic WG-DASL cohort but whose neuropathological diagnosis followed the same 141 
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criteria. The ROS/MAP RNAseq dataset is comprised of , and dorsolateral prefrontal cortex 142 
RNAseq data from 288 AD and 206 non-AD samples that are part of the ROS/MAP cohort 143 
(Table 1) previously described [18, 19]. were employed for replication of the associations that 144 
were detected with the WG-DASL gene expression measurements. Methodological details for 145 
the RNAseq data generation and eQTL analysis are provided in the Supplementary Methods. 146 
2.4. Statistical Analysis 147 
Normalized transcript expression levels, on a log2 scale, were tested for associations with 148 
TREM locus genotypes in each of the three datasets (Mayo WG-DASL, Mayo Clinic RNAseq 149 
and ROS/MAP RNAseq) via multivariable linear regression analyses implemented in PLINK 150 
[20]. An additive model was applied adjusting for age-at-death, sex, diagnosis, RNA Integrity 151 
Number (RIN) and adjusted RIN squared (RIN-RINmean)2 in all expression analyses, and APOE 152 
ε4 dosage and PCR plate in Mayo WG-DASL only, and flowcell in the Mayo Clinic RNAseq 153 
dataset only. The eQTL analysis in the discovery, WG-DASL dataset, included APOE ε4 dose as 154 
a covariate given the strong effect of this allele on AD. However, since a significant association 155 
was not detected with this covariate in the rs9357347 eQTL analyses in the discovery set, APOE 156 
 ε4 dose was not included in the eQTL analyses implemented on the replication cohorts. For 157 
comparison, we have performed the eQTL analyses in all three datasets with and without 158 
adjustment for APOE ε4 dose and do not observe a substantial difference in the association 159 
results between these two models. 160 
Meta-analyses were performed on eQTL results from the three independent datasets. For 161 
these analyses, METAL [21] was implemented using weighted average of z-scores from the 162 
individual study p-values, weighted according their sample size. 163 
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 164 
3. Results 165 
In the WG-DASL gene expression data from the temporal cortex (n=399) and cerebellum 166 
(n=374) of neuropathologically diagnosed AD and non-AD subjects (Table 1), we observed that 167 
of the 5 TREM locus coding genes, only TREML1 and TREM2 were reliably detected (Table S1 168 
and Fig. 2). TREML1 was detected in both the temporal cortex and cerebellum, while TREM2 169 
was reliably detected only in the temporal cortex. We validated TREML1 and TREM2 WG-170 
DASL temporal cortex gene expression measurements, using RNAseq data generated from a 171 
subset of 93 autopsied AD subjects who also had microarray data. There was highly significant 172 
correlation between WG-DASL and RNAseq measurements for both TREML1 (ßrs=0.65, p<10-173 
40) and TREM2 (rsß=0.80, p<10-40) (Fig. S1).  174 
Variants located within 100kb of the 5’ or 3’end of any TREM coding gene that 175 
demonstrated association with AD-risk in the IGAP stage I meta-analysis (17,800 AD vs. 37,154 176 
controls, p≤0.0015), were evaluated for their association with TREML1 expression in the 177 
temporal cortex and cerebellum, and with TREM2 expression in the temporal cortex. Of the 178 
1,002 variants tested at this locus in the IGAP stage I 1 meta-analysis, 28 had p-values ≤ 0.0015, 179 
and 16 of these have been genotyped in the autopsied samples in the Mayo Clinic brain 180 
expression genome-wide association study (Mayo eGWAS). We also assessed 5 other variants at 181 
this locus previously reported to be associated with either reduced AD-risk (rs3747742) [11], 182 
increased AD pathology burden and cognitive decline (rs6910730, rs7759295) [14], or decreased 183 
CSF tau levels (rs6916710, rs6922617) [13]. Table 2 shows the association of TREML1 and 184 
TREM2 gene expression with these 21 variants. In 399 combined AD and non-AD temporal 185 
cortex samples tested for the 16 IGAP variants, 5 SNPs achieved nominally significant 186 
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association showed association (uncorrected p<0.05) with increased levels of both TREML1 and 187 
TREM2 (rs9381040, rs2093395, rs9357347, rs9394778, rs9296359), and a sixth variant 188 
(rs9394767) was significantly associated with increased TREML1 levels only. As shown in Fig. 189 
3, four of the six variants that associate with increased levels of TREML1 and TREM2 are in a 190 
single LD block (block 2: rs9357347, rs9381040, rs2093395 and rs9394767) and in tight linkage 191 
disequilibrium with each other (r2≥0.90). Of these variants, rs9381040 is the strongesthas the 192 
most significant IGAP AD-risk associating association in SNP the IGAP stage 1 meta-analysisat 193 
the TREM locus (Table 2). This IGAP “hit” is located 5.5kb downstream from TREML2 and 194 
23.7kb upstream from TREM2 and is associated with TREML1 and TREM2 expression 195 
(p=0.0083, beta=0.086 and p=0.048, beta=0.091, respectively). Given that the expression 196 
measures were on a log2 scale, these changes in expression are equivalent to TREML1 and 197 
TREM2 fold-changes of 1.06 and 1.07, for each copy of the minor allele, respectively. Notably, 198 
the minor allele of the IGAP “hit” rs9381040 is associated with both decreased AD-risk and 199 
increased TREML1 and TREM2 levels. However, based on data from the Roadmap Epigenomics 200 
Consortium [22], rs9381040 lacks evidence of regulatory potential in brain regions relevant to 201 
AD.  202 
The variant with the strongest effectmost significant association on with brain TREML1 203 
expression, which also associates with TREM2 levels, is rs9357347 in block 2 (Fig. 3). This SNP 204 
is located 6.9kb downstream from TREML2 and 19.6kb upstream from TREM2 and is in tight 205 
LD with the IGAP “hit” rs9381040 (D’=0.99, r2=0.96). As expected, the minor allele of 206 
rs9357347 is associates associated with reduced AD-risk (OR=0.95, 95% CI=0.91-0.98, 207 
p=0.001) in the IGAP GWASmeta-analysis [12] and with increased TREML1 and TREM2 208 
expression in the temporal cortex in the Mayo Clinic WG-DASL eQTL analysis (p=0.0063, 209 
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beta=0.088 and p=0.046, beta=0.090, respectively) (Table 2 and Fig. S2). These beta 210 
coefficients can be interpreted as an estimated 1.06-fold change of both TREML1 and TREM2, 211 
per rs9357347 minor allele, in this temporal cortex dataset. Unlike the IGAP “hit” (rs9381040), 212 
rs9357347 lies within sequence subject to histone modifications and within a DNAse 213 
hypersensitive site detected by the Roadmap Epigenomics Consortium [22] in brain regions 214 
relevant to AD pathology such as the hippocampus. Furthermore, this variant, and it is predicted 215 
to affect transcription factor binding (SP1 and PPAR) as catalogued in HaploReg 216 
(http://www.broadinstitute.org/mammals/haploreg/haploreg.php)  [23]. Consequently, it has a 217 
strong compelling Regulome score of 2b (http://www.regulomedb.org/) due to the evidence of its 218 
regulatory potential [16] (Table 2). Indeed, of all the variants with an AD-risk p-value<0.0015 in 219 
the IGAP meta-analysis, and p-values<0.05 in our WG-DASL eQTL analysis of temporal cortex 220 
TREML1 and TREM2 gene expression levels, rs9357347 had the greatest regulatory potential as 221 
determined by their Regulome scores (Fig. S3 and Fig. S4). 222 
The other two variants with gene expression associations in the temporal cortex are in a 223 
different LD block (block 4: rs9394778 and rs9296359) and in strong tight LD with each other 224 
(r2 = 0.67). These SNPs are more strongly significantly associated with TREM2 than with 225 
TREML1 expression; however, neither has a strongcompelling evidence of regulatory potential 226 
as both have Regulome scores of 6 (Table 2). In the 374 AD and non-AD subjects with 227 
cerebellum expression measures, none of the 16 IGAP AD-risk associated variants that were 228 
tested, associate with TREML1 gene expression (p>0.05). 229 
We determined the extent of linkage disequilibrium (LD) between the likely regulatory 230 
variant rs9357347, the IGAP “hit” rs9381040 and the significant TREM2 rare missense AD-risk 231 
variants p.D87N (rs142232675) and p.R47H (rs75932628) [1]. As shown in Fig. 3, these two 232 
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TREM2 rare missense AD-risk variants are not in LD with either rs9357347 or rs9381040. This 233 
suggests that the protective effect of the regulatory rs9357347 and the IGAP “hit” are 234 
independent of the rare, missense TREM2 variants.  235 
We next evaluated LD amongst variants tested at this locus, including  common TREM 236 
locus variants previously reported to have associations with AD-risk (rs3747742) [11], increased 237 
AD pathology burden and cognitive decline (rs7759295 and rs6910730) [14], or with lower CSF 238 
ptau (rs6922617 and rs6916710) [13]. The missense TREML2 variant rs3747742 (p.S144G) is in 239 
LD with the regulatory variant implicated in our study, rs9357347. As reported, rs3747742 is 240 
also in LD with rs9381040 (IGAP hit); and as expected associates with reduced AD-risk 241 
(p=0.009), however with slightly lesser strongly significance than the AD-risk association of the 242 
regulatory rs9357347 (p=0.001) or the IGAP “hit” rs9381040 (0.0006). Further, the association 243 
of rs3747742 has less strong association with brain TREML1 expression is not as significant as 244 
that of rs9357347., In addition, rs3747742 has no association with brain TREM2 levels, and has a 245 
weak Regulome score of 6 (Table 2).  246 
Of the four common TREM locus variants that associate with AD endophenotypes, only 247 
rs6916710 is in strong tight LD with the regulatory rs9357347 (D’=0.91, r2=0.62). However, 248 
rs6916710, does not show significant association with AD-risk in the IGAP meta-analysis 249 
(p=0.103) nor with TREML1 or TREM2 gene expression levels (Table 2).  250 
None of the other three common TREM locus variants with reported AD-endophenotype 251 
associations are in tight strong LD with the regulatory rs9357347 or any of the other TREM locus 252 
variants that are associated with AD-risk. Only rs7759295 showed association with nominally 253 
significant TREML1 brain gene expression association (uncorrected p=0.04), but neither this nor 254 
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any of the other AD-endophenotype-associated SNPs have evidence of AD-risk association or 255 
strong Regulome scores that are indicative of likely regulatory function (Fig. 3 and Table 2). 256 
Utilizing publicly available RNAseq data from two independent cohorts (Table 1) that do 257 
not overlap with the samples included in the WG-DASL eQTL analysis, we sought replication of 258 
the rs9357347 association with TREML1 and TREM2. Although in the ROS/MAP RNAseq 259 
dataset a significant association was only detected with the levels of TREM2 the results were not 260 
replicated in the smaller of the two cohorts (Mayo RNAseq 84 AD and 48 non-AD: TREML1 261 
beta=-0.03, p=0.78; TREM2 beta=0.08, p=0.51), rs9357347 demonstrated suggestive association 262 
with increased TREML1 and TREM2 gene expression in the larger cohort (ROS/MAP RNAseq 263 
288 AD and 206 non-AD: TREML1 beta= 0.03, p=0.14 ; TREM2 beta=0.43, p=0.11) (Table 3). 264 
), Metameta-analysis from the three independent study p-values (Mayo WG-DASL, Mayo 265 
RNAseq and ROS/MAP RNAseq) yielded p-values that reached significant resultsce (TREML1 266 
p=9.33.4x10-3-2; TREM2 p=3.59.3x10-4-3), confirming the association of the rs9357347 minor 267 
allele with increased TREML1 and TREM2 gene expression. The strength evidence of association 268 
with TREM2 expression was strongergreater for the TREM2 association in this upon meta-269 
analysis compared to the association observed in our the initial discovery resultsdataset, ; 270 
whereas that forthe evidence of association with TREML1 expression was slightly weakergreater 271 
in our discovery dataset compared to the meta-analysis. 272 
4. Discussion 273 
In this study, we first sought to characterize the brain expression of TREM locus genes 274 
based on the premise that those TREM cluster genes that are expressed in the brain are likely to 275 
be candidate AD-risk genes. We determined that besides TREM2, only TREML1 has reliable 276 
expression in the brain regions we studied. Whereas TREML1 is expressed in both cerebellum 277 
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and temporal cortex of all subjects, TREM2 is expressed in the temporal cortex of 98% of 278 
temporal cortex all subjects but only inand 41% of cerebellum subjects samplesin the 279 
cerebellum. This suggests that cerebellar levels of TREM2 are lower than those for temporal 280 
cortex, consistent with previous reports showing higher gene levels in the temporal cortex than 281 
cerebellum [24] and higher protein levels correlating with AD neuropathology [25]. In contrast, 282 
TREM1, TREML2 and TREML4 are expressed in only 0%-17% of the subjects. While lack of 283 
reliable brain expression of these genes does not definitively rule them out as plausible AD-risk 284 
genes, our findings provide the strongest evidence for TREML1, besides TREM2, as most likely 285 
TREM locus genes for further studies in AD.  286 
Consequently, we focused our studies on TREML1 and TREM2; and utilized their brain 287 
expression levels as endophenotypes to identify putative regulatory variants that modify risk for 288 
AD. Focusing on brain TREML1 and TREM2 expression associations with variants at the TREM 289 
locus that also show evidence of AD-risk association in the publicly available IGAP meta-290 
analysis, we identified a putative regulatory variant, rs9357347, located between TREM2 and 291 
TREML2., Tthe minor allele of this variantwhich associates is associated with both decreased 292 
AD-risk and with increased TREML1 and TREM2 brain expression in the temporal cortex. The 293 
direction of effect of this variant on AD-risk and brain expression levels of these genes appears 294 
to be biologically congruent based on the known functions of these genes.  295 
TREML1, which is also known as TREM-like transcript 1 (TLT-1), is a myeloid receptor 296 
expressed exclusively in the α-granules of platelets and megakaryocytes [26]. Identification of 297 
higher levels of soluble TREML1 (sTLT-1) in septic patients vs. controls and development of 298 
hemorrhage in mice lacking Treml1 when exposed to inflammatory injury led to the conclusion 299 
that TREML1 functions to maintain vascular integrity during inflammation [27]. Further, 300 
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TREML1 was shown to dampen leukocyte activation during sepsis, and inhibited pro-301 
inflammatory activation of TREM1 by competing with its ligand [28]. These studies strongly 302 
support a role for TREML1 in promoting vascular homeostasis and limiting inflammation.   303 
Functional, in-vitro studies of TREM2 rare, missense mutations revealed reduced TREM2 304 
function as a consequence of decreased maturation and ectodomain shedding, also supported by 305 
findings of decreased soluble TREM2 levels in the cerebrospinal (CSF) levels of patients with 306 
these mutations [13, 29]. TREM2 deficiency also led to increased amyloid pathology and 307 
neuronal loss in the 5XFAD mouse model of AD [30]. Interestingly, TREM2 deficiency in an 308 
ischemic mouse model resulted in reduced phagocytosis and resorption of infarcted brain tissue, 309 
and worse neurological recovery [31]. Collectively, these findings support a neuroprotective role 310 
for TREM2 in various neuronal injury models. There are, however, studies with contradictory 311 
results for TREM2. In a different mouse model of AD (APP/PS1), knock-out of Trem2, resulted 312 
in reduction of macrophages infiltrating from the periphery, along with less brain inflammation 313 
and reduced amyloid and tau pathology [32]. These opposite findings of Trem2 knock-out could 314 
be due to differences in the mouse models of Alzheimer’s disease tested, different Trem2 315 
knockout mouse lines, and analyses performed at different time points (early stages versus later 316 
stages of Alzheimer’s disease). 317 
Given these collective data, a regulatory variant that enhances levels of TREML1 in 318 
platelets, and levels of TREM2 in brain resident microglia could conceivably promote vascular 319 
homeostasis and limit inflammatory damage to neurons in AD and potentially other nervous 320 
system diseases. Indeed, rs9357347 has strong compelling evidence of regulatory potential as it 321 
is located in a known DNase hypersensitive site and affects histone modification in the 322 
hippocampus and transcription factor binding, according to the evidence compiled in the 323 
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Regulome database and HaploReg [16, 23]. Interestingly, rs9357347 is predicted to affect 324 
transcription factor binding (SP1 and PPAR) as catalogued in HaploReg, . and tThese two 325 
transcription factors are known be important in regulating key players in the inflammatory 326 
response and lipid metabolism [33, 34]. Further, rs9357347 shows the strongest most significant 327 
association with TREML1 gene expression amongst variants at the TREM locus with IGAP meta-328 
analysis AD-risk p-values≤0.0015, in addition to its association with brain TREM2 levels.  329 
The regulatory rs9357347 SNP is in the same haplotype block as the strongest AD-risk 330 
associating variant with the most significant AD-risk association at the TREM locus in the IGAP 331 
meta-analysis, rs9381040, which is an intergenic variant downstream of TREML2. Though this 332 
IGAP TREM locus “hit” SNP has stronger greater evidence of AD-risk association than 333 
rs9357347, there is no evidence of regulatory potential for rs9381040 in brain regions relevant to 334 
AD.  335 
While the fold change estimates in gene expression associated with rs9357347-C are 336 
modest at 6-7%, the biological impact of the increase attributed to each copy of the minor allele, 337 
can be significant and may provide sufficient protection from disease in some individuals, 338 
particularly when considered over a lifetime. Furthermore, these estimates are based on RNA 339 
isolated from tissue samples and not microglial cells where both TREM2 and TREML1 are 340 
predominantly expressed [35], and where expression levels of these genes may be impacted to a 341 
greater extent by regulatory variants. Additional studies will be needed to determine the impact 342 
of such expression changes on the biology of microglial cell function. 343 
The TREML2 p.S144G variant [11], which associates with reduced AD-risk, is also in LD 344 
with both rs9357347 and rs9381040. Though proposed to be the functional variant that accounts 345 
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for the IGAP signal at this locus, TREML2 p.S144G is not predicted to have a functional 346 
consequence based on PolyPhen2 nor does it have evidence of regulatory potential. Further, 347 
TREML2 expression is too low to be reliably measured in brain tissue (TCX and CER). This , 348 
raisinges the possibility that the association with TREML2 p.S144G is due to its LD with a 349 
functional variant(s) that influences the function or level of a nearby TREM gene(s), such as 350 
TREML1 or TREM2. Alternatively, the protective effect of p.S144G could be mediated directly 351 
through the function of TREML2 in a cell with abundant expression, such as macrophages, in 352 
which TREML2 is known to be upregulated in response to inflammation, [36]. It is also possible 353 
that significant rs9357347 eQTL associations would be detected with TREML2 or other TREM 354 
locus transcripts in tissues were these genes are more abundantly expressed. 355 
Our findings therefore challenge the conclusion that p.S144G is the only functional 356 
variant accounting for the protective effect detected in the IGAP meta-analysis at this locus, and 357 
propose rs9357347 as an alternative functional variant with regulatory effects. In reality, both 358 
variants could have functional consequences and contribute to the IGAP signal. It should be 359 
emphasized that, as demonstrated in our LD analysis, TREM2 p.R47H is not in LD with these 360 
two variants, and thus affects AD-risk independently. Both rs9357347 and p.S144G should be 361 
tested for their functional potential and influence on outcomes of inflammation and 362 
neuroprotection. It remains possible that rs9357347 is in LD with an untested true functional 363 
variant with effects on transcription and AD-risk. It is likewise possible that while rs9357347 is 364 
associated with both AD-risk and gene expression levels, these joint effects are coincidental due 365 
to LD, rather than being related. These possibilities need to be explored through sequencing of 366 
the entire TREM locus, or via targeted sequencing of LD block 2 where rs9357347 resides.  367 
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Nevertheless Thus, our findings provide a testable hypothesis for a strong candidate functional 368 
variant, specific transcription factors and their effects on TREML1 and TREM2 levels.    369 
Furthermore, our investigation of variants previously shown to associate with AD-related 370 
endophenotypes [13-15] suggests that these are unlikely to be functional AD-risk variants per se, 371 
though it remains possible that they are markers of functional variants at the TREM locus.  372 
In summary, we characterized expression of TREM genes in cerebellum and temporal 373 
cortex,  and determined TREML1 and TREM2 to be the only reliably expressed TREM genes in 374 
these brain regions. ,We identified rs9357347 as a putative regulatory variant that is associates 375 
associated with protection from AD and with increased TREML1 and TREM2 brain levels, and 376 
nominate rs9357347 as one of the functional variants that accounts for the IGAP AD-risk signal. 377 
Additional studies are needed to validate the function of this variant, and to explore the 378 
possibility of the presence of other variants at this locus that could contribute to associations 379 
observed with rs9357347.  Importantly, these findings suggest a potential link between TREML1 380 
and TREM2, as well as vascular homeostasis and neuroinflammation as related mediators of 381 
neuronal protection and injury in AD and possibly other central nervous system diseases. 382 
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Figure Legends 498 
Fig. 1. TREM gene cluster on Chr 6p21.1. The chromosomal positions are based on the human 499 
genome assembly from February 2009 (GRCh37/hg19). There are seven RefSeq genes at the 500 
TREM locus (TREM1, TREML1, TREM2, TREML2, TREML3P, TREML4 and TREML5P); 501 
however, TREML3P and TREML5P are non-coding pseudogenes. The transcript figures are 502 
taken from the UCSC Genome Browser. 503 
Fig. 2. Location of TREML1 and TREM2 WG-DASL probes. 504 
The location of the (A) TREML1 and (B) TREM2 WG-DASL probes (highlighted in light blue) 505 
are shown relative to their Refseq transcripts. The chromosomal positions are based on the 506 
human genome assembly from February 2009 (GRCh37/hg19). As shown, both of these probes 507 
are complementary to all RefSeq transcripts for the respective gene. The transcript figures are 508 
taken from the UCSC Genome Browser.  509 
Fig. 3. LD Plot of TREM locus variants. 510 
LD plot of TREM locus variants where haplotype blocks were determined with the solid spine 511 
definition; square colors correspond to D’ (strong tight LD=warmer colors, weak LD=cooler 512 
colors) and r2 values are shown within the squares (Supplementary Methods). Red circles: The 513 
rare TREM2 AD-risk missense variants rs142232675 (p.D87N) and rs75932628 (p.R47H) [1]. 514 
Blue circles: Variants that associate with increased AD pathology burden and cognitive decline 515 
(rs7759295 and rs6910730) [14], or with lower CSF ptau (rs6922617 and rs6916710) [13]. 516 
Green circles: The variant with the strongest most significant AD-risk association in the IGAP 517 
meta-analysis (rs9381040); rs9357347, which has the most significantstrongest brain TREML1 518 
gene expression association, also shows association withhas brain TREM2 gene expression 519 
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association, IGAP AD-risk association and the best Regulome score within all tested SNPs; and 520 
rs9296359 which has the strongest brainmost significant association with TREM2 expression 521 
association. RefSeq gene transcripts are shown above the LD plot relative to the variant position 522 
according to the February 2009 human genome assembly (GRCh37hg19) across the targeted 523 
genomic region (TREM gene +/-100 kb: chr6:41016999-41354457). 524 
 525 
 526 
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Tables 
Table 1. Description of samples included in the discovery and replication cohorts utilized for eQTL analysis. 
  
Mayo Clinic WG-DASL Mayo Clinic RNAseq ROS/MAP RNAseq 
CER TCX TCX PFCX 
AD Non-AD AD  Non-AD AD  non-AD  AD non-AD 
N 197 177 202 197 84 48 288 206 
Mean age +/- SD 73.6 ± 5.6 71.7 ± 5.5 73.6 ± 5.5 71.6 ± 5.6 83.2 ± 8.7 85.7 ± 8.3 89.8 ± 5.8 86.5 ± 7.2 
Female, N (%) 101 (51%) 63 (36%) 108 (53%) 78 (40%) 48 (57%) 26 (54%) 186 (65%) 121 (59%) 
% APOE ε4+ 64% 25% 61% 25% 51% 17% 34% 12% 
 
Samples included in the Mayo Clinic eGWAS (discovery cohort), with cerebellar (CER) and temporal cortex (TCX) gene expression 
measurements from Illumina WG-DASL arrays have been previously described [17]. Samples in the Mayo Clinic RNAseq cohort 
(replication cohort #1) had temporal cortex gene expression measurements, and did not overlap with the Mayo eGWAS (WG-DASL) 
cohort. The ROS/MAP RNAseq cohort (replication cohort #2) had dorsolateral prefrontal cortex (PFCX) gene expression 
measurements, and did not overlap with the Mayo eGWAS (WG-DASL), or with the Mayo Clinic RNAseq cohort. The RNAseq data 
for these two cohorts is available at the Sage Synapse, AMP AD Knowledge Portal 
(https://www.synapse.org/#!Synapse:syn2580853/wiki/66722), under synapase IDs syn3388564 (ROS/MAP RNAseq) and 
syn3163039 (Mayo RNAseq). 
26 
 
Table 2. Association of variants at the TREM locus with AD-risk and TREM WG-DASL brain gene expression levels. 
  
 
 
 
Chr 
SNP 
Position  
hg19 
AD-Risk (IGAP StageI Meta-analysis) Brain eQTL (Mayo Clinic eGWAS) Regulome
Score 
HapMap 
CEU    
MAF 
Effect 
Allele 
Non 
Effect 
 
Beta SE Pvalue TREML1 
CER 
 
TREML1 
CER        
 
TREML1 
TCX 
 
TREML1 
TCX        
 
TREM2 
TCX 
 
TREM2 
TCX         
 
6 rs9381040 41,154,650 T C -0.0588 0.0171 5.97E-04 0.021 2.3E-01 0.086 8.3E-03 0.091 4.8E-02 NA 26.70% 
6 rs2093395 41,155,026 C G -0.0586 0.0172 6.40E-04 0.021 2.3E-01 0.086 8.3E-03 0.091 4.8E-02 6 27.90% 
6 rs2038568 41,158,132 C G 0.1272 0.0379 7.93E-04 0.018 7.8E-01 -0.080 3.9E-01 -0.186 1.6E-01 5 8.30% 
6 rs12194214 41,028,574 C A 0.1443 0.0432 8.36E-04 -0.081 9.4E-02 -0.104 2.7E-01 -0.129 3.2E-01 6 4.20% 
6 rs9462675 41,153,238 A G 0.1374 0.0416 9.54E-04 -0.015 7.5E-01 -0.114 1.6E-01 -0.207 6.5E-02 5 3.60% 
6 rs6933067 41,133,522 C T 0.1409 0.0431 1.07E-03 -0.013 7.6E-01 -0.098 2.1E-01 -0.134 2.1E-01 7 3.50% 
6 rs9357347 41,150,591 C A -0.0554 0.017 1.10E-03 0.013 4.6E-01 0.088 6.3E-03 0.090 4.6E-02 2b 28.10% 
6 rs9394767 41,159,905 G A -0.0559 0.0172 1.14E-03 0.011 5.7E-01 0.096 6.5E-03 0.083 1.0E-01 5 28.80% 
6 rs1542638 41,286,604 G A 0.0544 0.0167 1.14E-03 -0.022 2.2E-01 -0.035 2.9E-01 -0.064 1.6E-01 4 28.30% 
6 rs9471491 41,153,622 A C 0.1401 0.0436 1.31E-03 -0.015 7.5E-01 -0.114 1.6E-01 -0.207 6.5E-02 7 3.50% 
6 rs9471495 41,157,372 A C 0.1364 0.0427 1.40E-03 0.014 8.3E-01 -0.099 2.9E-01 -0.235 7.2E-02 7 3.50% 
6 rs9462677 41,158,856 A T 0.1388 0.0435 1.41E-03 0.016 8.1E-01 -0.099 2.9E-01 -0.235 7.3E-02 7 4.30% 
6 rs9394778 41,215,058 A G -0.0494 0.0155 1.44E-03 0.015 3.3E-01 0.065 2.7E-02 0.099 1.5E-02 6 39.80% 
6 rs9471494 41,157,344 G C 0.1359 0.0427 1.46E-03 0.010 8.7E-01 -0.102 2.6E-01 -0.221 8.2E-02 6 4.50% 
6 rs6912013 41,061,593 C T 0.1377 0.0433 1.48E-03 -0.076 1.2E-01 -0.104 2.7E-01 -0.124 3.4E-01 5 2.70% 
6 rs9296359 41,205,690 A G -0.0518 0.0163 1.48E-03 0.017 2.8E-01 0.066 2.4E-02 0.116 4.6E-03 6 27.40% 
6 rs3747742* 41,162,518 C T -0.0455 0.0173 8.56E-03 0.018 2.9E-01 0.072 2.3E-02 0.064 1.5E-01 6 28.30% 
6 rs6916710* 41,164,788 T C -0.0265 0.0163 1.03E-01 0.013 4.3E-01 0.054 7.7E-02 0.072 9.2E-02 7 38.40% 
6 rs7759295* 41,135,850 T C -0.0228 0.0252 3.66E-01 -0.023 3.5E-01 0.094 4.0E-02 -0.008 9.0E-01 6 13.30% 
6 rs6910730* 41,246,633 G A -0.0103 0.0254 6.86E-01 -0.046 8.5E-02 -0.079 1.2E-01 -0.032 6.5E-01 4 8.40% 
6 rs6922617* 41,336,101 A G -0.0121 0.0312 6.98E-01 -0.033 2.6E-01 -0.098 7.4E-02 0.011 8.9E-01 7 8.50% 
Chr SNP Position  hg19 
AD-Risk (IGAP Stage1 Meta-analysis) Brain eQTL (Mayo Clinic eGWAS) 
Regulome
Score 
HapMap CEU    
MAF Effect 
Allele 
Non 
Effect 
Allele 
OR (95% CI) P-value 
TREML1 
CER 
BETA 
TREML1 
CER        
P 
TREML1 
TCX 
BETA 
TREML1 
TCX        
P 
TREM2 
TCX 
BETA 
TREM2 
TCX         
P 
6 rs9381040 41,154,650 T C 0.94 (0.91 - 0.98) 5.97E-04 0.021 2.30E-01 0.086 8.30E-03 0.091 4.80E-02 NA 26.70% 
Formatted: Left, Line spacing:  Double
Formatted: Left, Indent: First line:  0"
Formatted: Left
Formatted: Left, Line spacing:  Double
Formatted: Left, Line spacing:  Double
Formatted: Left, Line spacing:  Double
Formatted: Left, Line spacing:  Double
Formatted: Left, Line spacing:  Double
Formatted: Left, Line spacing:  Double
Formatted: Left, Line spacing:  Double
Formatted: Left, Line spacing:  Double
Formatted: Left, Line spacing:  Double
Formatted: Left, Line spacing:  Double
Formatted: Left, Line spacing:  Double
Formatted: Left, Line spacing:  Double
Formatted: Left, Line spacing:  Double
Formatted: Left, Line spacing:  Double
Formatted: Left, Line spacing:  Double
Formatted: Left, Line spacing:  Double
Formatted: Left, Line spacing:  Double
Formatted: Left, Line spacing:  Double
Formatted: Left, Line spacing:  Double
Formatted: Left, Line spacing:  Double
Formatted: Left, Line spacing:  Double
Formatted: Left, Line spacing:  Double
Formatted Table
Formatted: Tab stops:  0.8", Left
Formatted: Highlight
Formatted: Highlight
27 
 
6 rs2093395 41,155,026 C G 0.94 (0.91 - 0.98) 6.40E-04 0.021 2.30E-01 0.086 8.30E-03 0.091 4.80E-02 6 27.90% 
6 rs2038568 41,158,132 C G 1.14 (1.05 - 1.23) 7.93E-04 0.018 7.80E-01 -0.08 3.90E-01 -0.186 1.60E-01 5 8.30% 
6 rs12194214 41,028,574 C A 1.16 (1.06 - 1.26) 8.36E-04 -0.081 9.40E-02 -0.104 2.70E-01 -0.129 3.20E-01 6 4.20% 
6 rs9462675 41,153,238 A G 1.15 (1.06 - 1.25) 9.54E-04 -0.015 7.50E-01 -0.114 1.60E-01 -0.207 6.50E-02 5 3.60% 
6 rs6933067 41,133,522 C T 1.15 (1.06 - 1.25) 1.07E-03 -0.013 7.60E-01 -0.098 2.10E-01 -0.134 2.10E-01 7 3.50% 
6 rs9357347 41,150,591 C A 0.95 (0.91 - 0.98) 1.10E-03 0.013 4.60E-01 0.088 6.30E-03 0.09 4.60E-02 2b 28.10% 
6 rs9394767 41,159,905 G A 0.95 (0.91 - 0.98) 1.14E-03 0.011 5.70E-01 0.096 6.50E-03 0.083 1.00E-01 5 28.80% 
6 rs1542638 41,286,604 G A 1.06 (1.02 - 1.09) 1.14E-03 -0.022 2.20E-01 -0.035 2.90E-01 -0.064 1.60E-01 4 28.30% 
6 rs9471491 41,153,622 A C 1.15 (1.05 - 1.26) 1.31E-03 -0.015 7.50E-01 -0.114 1.60E-01 -0.207 6.50E-02 7 3.50% 
6 rs9471495 41,157,372 A C 1.15 (1.05 - 1.25) 1.40E-03 0.014 8.30E-01 -0.099 2.90E-01 -0.235 7.20E-02 7 3.50% 
6 rs9462677 41,158,856 A T 1.15 (1.05 - 1.25) 1.41E-03 0.016 8.10E-01 -0.099 2.90E-01 -0.235 7.30E-02 7 4.30% 
6 rs9394778 41,215,058 A G 0.95 (0.92 - 0.98) 1.44E-03 0.015 3.30E-01 0.065 2.70E-02 0.099 1.50E-02 6 39.80% 
6 rs9471494 41,157,344 G C 1.15 (1.05 - 1.25) 1.46E-03 0.01 8.70E-01 -0.102 2.60E-01 -0.221 8.20E-02 6 4.50% 
6 rs6912013 41,061,593 C T 1.15 (1.05 - 1.25) 1.48E-03 -0.076 1.20E-01 -0.104 2.70E-01 -0.124 3.40E-01 5 2.70% 
6 rs9296359 41,205,690 A G 0.95 (0.92 - 0.98) 1.48E-03 0.017 2.80E-01 0.066 2.40E-02 0.116 4.60E-03 6 27.40% 
6 rs3747742* 41,162,518 C T 0.96 (0.92 - 0.99) 8.56E-03 0.018 2.90E-01 0.072 2.30E-02 0.064 1.50E-01 6 28.30% 
6 rs6916710* 41,164,788 T C 0.97 (0.94 - 1.01) 1.03E-01 0.013 4.30E-01 0.054 7.70E-02 0.072 9.20E-02 7 38.40% 
6 rs7759295* 41,135,850 T C 0.98 (0.93 - 1.03) 3.66E-01 -0.023 3.50E-01 0.094 4.00E-02 -0.008 9.00E-01 6 13.30% 
6 rs6910730* 41,246,633 G A 0.99 (0.94 - 1.04) 6.86E-01 -0.046 8.50E-02 -0.079 1.20E-01 -0.032 6.50E-01 4 8.40% 
6 rs6922617* 41,336,101 A G 0.99 (0.93 - 1.05) 6.98E-01 -0.033 2.60E-01 -0.098 7.40E-02 0.011 8.90E-01 7 8.50% 
 
Shown are Vvariants located within 100kb of a TREM gene and that had an AD-risk p ≤ 0.0015 in the IGAP stage 1 meta-analysis 
(top 16 rows); ), as well as and 5 common TREM locus variants with previous reports of AD-risk or endophenotype association 
(bottom 5 rows, SNP marked with an *). AD-risk association results are from the publicly available IGAP meta-analysis stage 1. Brain 
gene expression associations are from the Mayo Clinic eGWAS and based on cerebellar (CER) and temporal cortex (TCX) gene 
expression measurements with Illumina WG-DASL arrays with TREML1 probe ILMN_1690783 and TREM2 probe ILMN_1701248. 
Variants showing association with nominally significant braingene expression associations (uncorrected p<0.05) are underlined and in 
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italic font. The variant with the strongest most significant AD-risk association in the IGAP meta-analysis (rs9381040), and the variant 
with the strongest most significant gene expression association and best Regulome score (rs9357347) are in bold font. OR (95% CI): 
odds ratio and 95% confidence interval. Given that the eGWAS expression measures were on a log2 scale, fold-change for the Mayo 
eGWAS beta coefficients = 2beta. 
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Table 3. Meta-analysis of rs9357347 eQTL results from three independent datasets.  
Dataset 
Sample 
size 
TREML1 TREM2 
beta p   beta p 
Mayo WG-DASL 380 0.088 6.3x10-3 
 
0.09 4.6x10-2 
Mayo Clinic RNAseq 132 -0.03 0.78 
 
0.08 0.51 
ROS/MAP RNAseq 494 0.03 0.14  0.43 0.11 
Meta-analysis 1006 +-+ 9.3x10-3   +++ 9.3x10-4 
 
Dataset Sample size MAF 
TREML1  TREM2 
beta SE p  beta SE p 
Mayo WG-DASL 380 0.307 0.088 0.032 6.28E-03  0.090 0.045 4.61E-02 
Mayo Clinic RNAseq 132 0.311 -0.030 0.108 7.82E-01  0.084 0.128 5.13E-01 
ROS/MAP RNAseq 494 0.281 0.089 0.114 4.36E-01  0.124 0.060 3.77E-02 
Meta-analysis 1006   +-+   3.36E-02  +++   3.54E-03 
 
 
Meta-analysis of rs9357347 eQTL results from temporal cortex (Mayo WG-DASL and Mayo 
Clinic RNAseq) and dorsolateral prefrontal cortex samples (ROS/MAP). MAF = minor allele 
frequency. SE = standard error. Since in all three datasets the expression measures analyzed were 
on a log2 scale, fold-change for the beta coefficients = 2beta. The meta-analysis was performed 
using METAL, with weighted average of z-scores from the individual study p-values, weighted 
according their sample size. 
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 47 
Supplementary Methods 48 
IGAP AD-risk meta-analysis 49 
AD-risk association results shown in this study were obtained from the International 50 
Genomics of Alzheimer's Project (IGAP) stage 1 AD-risk GWAS meta-analysis [1]. The IGAP 51 
AD-risk meta-analysis is a large two-stage study based upon genome-wide association studies 52 
(GWAS) on individuals of European ancestry. In stage 1, IGAP used genotyped and imputed 53 
data on 7,055,881 single nucleotide polymorphisms (SNPs) to meta-analyze four previously-54 
published GWAS datasets consisting of 17,008 Alzheimer's disease cases and 37,154 controls 55 
(The European Alzheimer's disease Initiative – EADI, the Alzheimer Disease Genetics 56 
Consortium – ADGC, The Cohorts for Heart and Aging Research in Genomic Epidemiology 57 
consortium – CHARGE, The Genetic and Environmental Risk in AD consortium – GERAD). In 58 
stage 2, 11,632 SNPs were genotyped and tested for association in an independent set of 8,572 59 
Alzheimer's disease cases and 11,312 controls. Finally, a meta-analysis was performed 60 
combining results from stages 1 & 2.  61 
3 
 
Mayo Clinic WG-DASL eQTL dataset 62 
Total RNA, utilized in the array-based Illumina WG-DASL discovery cohort (Table 1) 63 
was isolated from frozen brain tissue using the Ambion RNAqueous kit and assessed for RNA 64 
quality and quantity using the Agilent RNA 6000 Nano Chip and Agilent 2100 Bioanalyzer. 65 
Only samples with an RNA integrity number (RIN) score ≥5 were used. All subjects were from 66 
the Mayo Clinic Brain Bank and underwent neuropathological evaluation by DWD. All ADs had 67 
a Braak score of ≥4.0 and non-ADs a Braak score of ≤2.5. Many of the non-ADs had unrelated 68 
pathologies. All ADs had a definite diagnosis according to the National Institute of Neurological 69 
and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders 70 
Association (NINCDS-ADRDA) criteria [2]. 71 
Expression measures were generated as described previously [3]. Briefly, samples were 72 
randomized across plates and chips prior to array processing. Internal replicates were included 73 
for quality control purposes. PCR and array processing was conducted at the Mayo Clinic 74 
Medical Genome Facility Gene Expression Core in accordance with the manufactures’ protocols. 75 
Raw probe data was exported from GenomeStudio (Illumina Inc) and the lumi package of 76 
Bioconductor [4, 5] was used for background subtraction, variance stabilizing transformation and 77 
quantile normalization.  78 
Although there are seven RefSeq genes at the TREM locus (TREM1, TREML1, TREM2, 79 
TREML2, TREML3P, TREML4 and TREML5P) (Fig. 1), TREML3P and TREML5P are non-80 
coding pseudogenes for which there are no probes on the WG-DASL array. Only transcripts 81 
whose expression was detected above background in ≥ 50% of the samples tested (Table S1) 82 
were evaluated for their associations with TREM locus variants (Table 2). The location of the 83 
WG-DASL probes relative to the transcripts is shown in Fig. 2. The probes were determined to 84 
4 
 
be complementary to sequences lacking known polymorphisms based on the human genome 85 
assembly from March 2006 (NCBI36/hg18).  86 
Mayo Clinic RNAseq dataset 87 
Temporal cortex RNAseq data from 84 LOAD and 48 non-AD brains from the Mayo 88 
Clinic Brain Bank that were not part of the Mayo Clinic WG-DASL eGWAS cohort but whose 89 
neuropathological diagnosis followed the same criteria (Table 1), were employed for replication 90 
of the associations that were detected with the WG-DASL gene expression measurements. Total 91 
RNA, utilized for the RNAseq replication cohort was extracted using Trizol® reagent and 92 
cleaned using Qiagen RNeasy columns with DNase treatment. Samples were randomized prior to 93 
the transfer of 40 (TCX) or 50 (CER) ng/ul of RNA to the Mayo Clinic Medical Genome Facility 94 
Gene Expression and Sequencing Cores for library preparation and sequencing. The TruSeq 95 
RNA Sample Prep Kit (Illumina, San Diego, CA) was used for library preparation. The library 96 
concentration, size distribution and RIN were measured on an Agilent Technologies 2100 97 
Bioanalyzer. Only samples with a RIN score >5 were used. Sequencing was performed on the 98 
Illumina HiSeq2000 using 101 base-pair (bp), paired end sequencing, with triplicate 99 
multiplexing of barcoded samples (3 samples per flowcell lane). Base-calling was performed 100 
using Illumina’s RTA 1.18.61 or RTA 1.17.21.3. FASTQ sequence reads were aligned to the 101 
human reference genome using TopHat 2.0.12 [6] and Bowtie 1.1.0 [7], and Subread 1.4.4 was 102 
used for gene counting [8].  FastQC was used for quality control (QC) of raw sequence reads, 103 
and RSeQC was used for QC of mapped reads. Raw read counts were normalized using 104 
Conditional Quantile Normalization (CQN) via the Bioconductor package; accounting for 105 
sequencing depth, gene length, and GC content. RNAseq data for this cohort is available at the 106 
Sage Synapse, AMP AD Knowledge Portal 107 
Deleted: Normalized transcript brain expression 
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(https://www.synapse.org/#!Synapse:syn2580853/wiki/66722), under synapase ID syn3163039 116 
(Mayo RNAseq). 117 
Genotypes for  rs9357347 were obtained using a TaqMan® SNP genotyping assay, 118 
C___2814743_10. Genotyping was performed at the Mayo Clinic in Jacksonville using an ABI 119 
PRISM 7900HT Sequence Detection System with 384-Well Block Module from (Applied 120 
Biosystems, Foster City, California). The genotype data was analyzed using the SDS software 121 
version 2.2.3 (Applied Biosystems).  122 
 123 
Religious Orders Study and the Rush Memory and Aging Project (ROS/MAP) 124 
RNAseq dataset 125 
RNA was isolated from frozen dorsolateral prefrontal cortex tissue of ROS/MAP subjects 126 
[18, 19] using the miRNeasy Mini Kit and RNase-Free DNase Set (Qiagen, Germantown, MD). 127 
RNA concentration and quality were determined using a Nanodrop (Thermo Fisher Scientific, 128 
Wilmington, DE) and Bioanalyzer (Agilent Technologies, Santa Clara, CA), respectively. Only 129 
samples with a RIN score >5 were used for library construction, which was assembled using 130 
50ng/ul of RNA for the strand-specific dUTP method. The library was read using Illumina HiSeq 131 
with 101 base pair paired-end reads and a goal coverage of >85 million paired-end reads. FPKM 132 
(Fragments per Kilobase of Exon Per Million Fragments Mapped) were quantile normalized with 133 
Combat correcting for batch.  RNAseq data for this cohort is available at the Sage Synapse, AMP 134 
AD Knowledge Portal (https://www.synapse.org/#!Synapse:syn2580853/wiki/66722), under 135 
synapase IDs syn3388564 (ROS/MAP RNAseq).  136 
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Genotypes for rs9357437 were obtained from three subsets of subjects. Genotypes for the 137 
first two subsets were generated in 2009 on the Affymetrix Genechip 6.0 platform (Affymetrix, 138 
Inc, Santa Clara, CA, USA) at the Broad Institute’s Center for Genotyping or the Translational 139 
Genomics Research Institute. The third subset was genotyped in 2012 on the Illumina 140 
HumanOmniExpress platform (Illumina, Inc, San Diego, CA, USA) at the Children’s Hospital of 141 
Philadelphia. All three data sets underwent the same quality control (QC) analysis (genotype call 142 
rate > 95%, Hardy Weinberg Equilibrium > 0.001).  Using Beagle software (version: 3.3.2), 143 
dosage data was imputed for all genotyped samples who passed QC using the 1000 Genomes 144 
Project (2011, Phase 1b) as a reference  145 
 146 
Determination of linkage disequilibrium 147 
Linkage disequilibrium of variants at the TREM locus (Fig. 3) was evaluated in the Mayo 148 
Clinic AD-risk GWAS HapMap2 imputed dataset (815 AD, 1218 controls) using Haploview 4.0 149 
[9]. TREM2 AD-risk missense variants rs142232675 (p.D87N) and rs75932628 (p.R47H) were 150 
not present in the Mayo GWAS HapMap2 imputed dataset, but were directly genotyped in the 151 
Mayo Clinic samples with TaqMan® assays, and were included to show their LD with variants 152 
that associate with AD-risk in the IGAP meta-analysis. Sixteen variants located within 100kb of 153 
a TREM gene and that had an AD-risk p0.0015 in the IGAP stage 1 meta-analysis are included, 154 
in addition to two rare missense TREM2 coding variants [rs142232675 (p.D87N), and 155 
rs75932628 (p.R47H)] and 5 common TREM locus SNPs with prior reports of AD-risk 156 
(rs3747742) [10] or endophenotype (rs7759295, rs6910730, rs6922617, rs6916710) [11, 12] 157 
association, even though they did not meet the IGAP AD-risk association cutoff.   158 
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Supplementary Results 205 
Assessment of potential collider conditioning bias 206 
Since the primary goal of this study was to estimate the effect of genetic variants on gene 207 
expression, rather than their effect on disease status, we combined ADs and non-ADs in the 208 
linear regression analysis and included diagnosis as a covariate. The diagnosis covariate was 209 
coded as the presence or absence of AD. However, adjusting for diagnosis status could 210 
potentially introduce a collider conditioning bias if both the genotype and the expression levels 211 
are associated with disease status [13]. Therefore, we have also analyzed the combined set of 212 
AD+nonAD, without adjustment for disease status, in order to determine if the effect of genotype 213 
on expression disappears or remains in the latter analysis. Table S2, shows results for the two 214 
types of analyses that were performed in each of the three datasets (Mayo WG-DASL, Mayo 215 
RNAseq and ROS/MAP RNAseq): (1) AD and nonAD combined while adjusting for diagnosis, 216 
(2) AD and nonAD combined not adjusting for diagnosis. Overall, the results from analyses 1 217 
and 2 are very similar, suggesting that there is no real impact of a collider effect.   218 
 219 
Effect of RIN on percent detection and rs9357347 eQTL association  220 
Fig. S6 shows TREML1 and TREM2 detection percentage stratified by RIN, and demonstrates 221 
that neither TREML1 nor TREM2 detection percentage is affected by RIN. Table S3 shows 222 
results of the rs9357347 eQTL associations in the Mayo WG-DASL dataset when stratifying by 223 
samples above and below the median RIN of 6.5 (Table S3). These results indicate that RIN 224 
does not significantly impact the magnitude of the rs9357347 eQTL associations, as the 225 
Formatted: Highlight
Formatted: Highlight
Formatted: Highlight
Formatted: Highlight
Formatted: Highlight
Formatted: Highlight
Formatted: Highlight
Formatted: Highlight
Formatted: Highlight
Formatted: Highlight
8 
 
estimates of the beta coefficients overlap with those observed in the analysis not stratified by 226 
RIN (Table S2). Although the significance of the association is lessened in the stratified 227 
analysis, this is likely due to the smaller sample size of the stratified groups compared to the 228 
sample size of the combined analysis. 229 
 230 
Association of rs9357347 with Braak stage 231 
Given the association of rs9357347 with AD-risk, we tested the hypothesis that this 232 
variant could also show an association with Braak stage, as the latter is an important criterion for 233 
the neurophathological diagnosis of AD [14]. Implementing an ANOVA model in R that 234 
included age-at-death, sex and APOE 4 dose (0, 1 or 2 alleles), in the two larger datasets (Mayo 235 
WG-DASL and ROS/MAP RNAseq), we determined that rs9357347 does not significantly 236 
contribute to the variance in Braak stage in either of these two cohorts (p=0.91 and p=0.27, 237 
respectively). In addition, we implemented linear regression analysis in R, again using the two 238 
larger datasets to estimate the effect of each copy of the rs9357347 minor allele on Braak stage, 239 
including age-at-death, sex and APOE 4 dose in the model. As shown in Table S4, we did not 240 
detect a significant association of rs9357347 with Braak stage in either cohort.   241 
 242 
Association of rs9357347 with cognition 243 
We also evaluated the association of rs9357347 with measures of global cognitive decline 244 
and global cognition at the last evaluation before death in the ROS/MAP cohort. In this dataset, 245 
global cognition is a variable for overall cognitive function measured by the raw scores from 19 246 
different tests that are converted to z scores and averaged. Global cognitive decline is a 247 
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longitudinal cognitive phenotype based on repeated measures of global cognition, as previously 249 
described [15, 16]. The analysis was performed using linear regression analysis implemented in 250 
R, under an additive model for rs9357347, and adjusting for age-at-death, sex and APOE 4 251 
dose. Neither global cognitive decline nor global cognition at last evaluation shows an 252 
association with rs9357347 in this cohort (Table S5).   253 
 254 
Association of age with TREML1 and TREM2 expression 255 
As the WG-DASL cohort was overall younger than the two RNAseq cohorts, we assessed 256 
the association of the age covariate on TREML1 and TREM2 gene expression levels in the linear 257 
regression model described in the Material & Methods section 2.4. Age was not significantly 258 
associated with either TREML1 or TREM2 expression in the Mayo WG-DASL cohort (p>0.05). 259 
On the other hand, both in the Mayo RNAseq and ROS/MAP RNAseq cohorts, TREML1 and 260 
TREM2 expression levels appeared to be slightly increased with age, albeit the magnitude of the 261 
effect sizes were modest, with beta coefficients equivalent to approximately a 1.01 and 1.03-fold 262 
change in expression levels (Mayo RNAseq: TREML1 p=0.085, beta=0.01; TREM2 p=0.026, 263 
beta=0.02. ROS/MAP RNAseq: TREML1 p=2.0x10-3, beta=0.04; TREM2 p=4.4x10-5, 264 
beta=0.03). Since TREML1 and TREM2 gene expression levels appear be increased with age, it 265 
is possible that this might have led to a decrease in power to detect an association of rs9357347-266 
C  with increased levels of these genes in the two older cohorts.  267 
 268 
Association of diagnosis with TREML1 and TREM2 expression  269 
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To assess if diagnosis is associated with TREML1 and/or TREM2 gene expression levels, linear 271 
regression analyses were performed in R in each of the three datasets, adjusting for all other 272 
covariates included in the eQTL analyses described in the Materials and Methods section 2.4, as 273 
well as rs9357347 minor allele dose. The box plots in Fig. S5 show the direction of the change in 274 
expression between AD and nonAD subjects, and indicate the significance of the association for 275 
each test. We observe a consistent trend of higher TREML1 and TREM2 expression in AD versus 276 
nonADs, although some of these associations do not reach statistical significance. The trend 277 
toward higher TREML1 and TREM2 expression in AD subjects could be a reflection of 278 
microglial activation and/or proliferation known to occur in AD brains.   279 
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Supplementary Table 
Table S1. Percent detection of TREM locus transcripts. 
 
         Mayo WG‐DASL: Cerebelluma 
Mayo WG‐DASL:       
Temporal Cortexb 
 Mayo Clinic 
RNAseq: Temporal 
Cortexc 
ROS/MAP RNAseq: 
DFPCd 
Symbol  Ensembl Gene ID  WG‐DASL Probe ID 
AD +   
non‐
AD 
AD  nonAD 
AD +   
non‐
AD 
AD  Non‐AD  AD + non‐AD  AD + non‐AD 
TREM1  ENSG00000124731 
ILMN_168823
1  0.00  0.00  0.00  0.25  0.00  0.51  18.18  66.99 
TREML
1 
ENSG0000016191
1 
ILMN_169078
3  100.00  100.00  100.00  100.00  100.00  100.00  100.00  97.84 
TREM2  ENSG00000095970 
ILMN_170124
8  40.91  43.59  37.29  98.25  99.50  96.95  100.00  100.00 
TREML
2 
ENSG0000011219
5 
ILMN_174086
4  17.38  17.44  17.51  6.27  10.40  2.03  8.33  24.75 
TREML
4 
ENSG0000018805
6 
ILMN_220532
2  6.15  4.62  7.91  2.26  2.97  1.52  2.27  15.13 
 
The percentage of samples with detectable expression of TREM family transcripts in each of the expression datasets studied. For the 
WG-DASL dataset (a,b) the corresponding WG-DASL probe is indicated. Only TREML1 and TREM2 expression are detectable above 
background in at least 50% of the Mayo WG-DASL samples tested (a,b), in at least one tissue; c: A detection threshold >-1, for cqn 
normalized expression levels was used to determine percent detection; d: percent detection was calculated as the proportion of subjects 
who express > 0 FPKM, DFPC = dorsolateral prefrontal cortex. The WG-DASL array lacked probes for the two TREM pseudogenes; 
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therefore they were not measured in the Mayo WG-DASL cohort. Expression levels were not available for the TREM pseudogenes in 
the ROS/MAP dataset. Based on the Mayo RNAseq dataset, the percent detection of TREML3P and TREML5P in temporal cortex are 
15% and 5% respectively.
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Table S2. Analyses to assess the potential of introducing collider conditioning bias in the 
linear regression model due to adjustment for diagnosis.  
         TREML1  TREM2 
Dataset  Group  N  beta  SE  p‐value   beta  SE  p‐value  
Mayo WG‐DASL:       
Temporal Cortex 
All (W/Dx)a  380  0.088  0.032  6.28E‐03  0.090  0.045  4.61E‐02 
All (Wo/Dx)b  380  0.083  0.033  1.32E‐02  0.088  0.045  5.33E‐02 
Mayo Clinic 
RNAseq: Temporal 
Cortex 
All (W/Dx)a  132  ‐0.030  0.108  7.82E‐01  0.084  0.128  5.13E‐01 
All (Wo/Dx)b  132  ‐0.023  0.111  8.40E‐01  0.102  0.145  4.86E‐01 
ROS/MAP RNAseq: 
DFPC 
All (W/Dx)a  494  0.089  0.114  4.36E‐01  0.124  0.060  3.77E‐02 
All (Wo/Dx)b  494  0.089  0.114  4.35E‐01  0.125  0.060  3.81E‐02 
 
For each of the three datasets, linear regression analysis was run in a: AD and non-AD 
combined, with diagnosis included as a covariate; b: Analysis of AD and non-AD combined, 
without adjustment for diagnosis.  N = sample size. SE= standard error. DFPC = dorsolateral 
prefrontal cortex. Given that all expression measures were on a log2 scale, fold-change for the 
beta coefficients = 2beta.  
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Table S3. Association of the TREM locus candidate regulatory variant, rs9357347, with 
TREML1 and TREM2 gene expression stratified by RIN. 
Gene 
Symbol  RIN group  N  beta  SE  p‐value  
TREML1 
RIN < 6.5  188  0.087  0.042  0.043 
RIN > 6.5  192  0.084  0.046  0.069 
TREM2 
RIN < 6.5  188  0.110  0.063  0.084 
RIN > 6.5  192  0.075  0.065  0.250 
 
Data shown for Mayo WG-DASL temporal cortex (AD+Non-AD) dataset. Samples were 
stratified into two groups representing those with a RIN below the median RIN of 6.5 and those 
with a RIN above 6.5. N = sample size. SE= standard error. Given that all expression measures 
were on a log2 scale, fold-change for the beta coefficients = 2beta. 
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Table S4. Association of rs9357347 with Braak stage. 
Dataset  N  beta  SE  p‐value  
Mayo WG‐DASL: Temporal Cortex  399  ‐0.139  0.160  0.387 
ROS/MAP RNAseq: DFPC  492  0.053  0.081  0.515 
 
The two largest cohorts were evaluated: Mayo WG-DASL and ROS/MAP RNAseq. The variant 
was tested for association with Braak stage using linear regression under an additive model and 
including age-at-death, sex and APOE 4 dose as covariates. In this model, the beta coefficient is 
interpreted as the change in Braak score associated with each copy of the minor allele. N = 
sample size. SE= standard error. DFPC = dorsolateral prefrontal cortex. 
 
  
Formatted: Font: 12 pt, Highlight
Formatted: Space After:  0 pt
Formatted: Highlight
Formatted: Highlight
Formatted: Highlight
Formatted: Highlight
Formatted: Font: 12 pt, Not Bold, Highlight
Formatted: Font: 12 pt, Not Bold, Italic,
Highlight
Formatted: Font: 12 pt, Not Bold, Highlight
Formatted: Highlight
Formatted: Font: 12 pt, Not Bold, Highlight
Formatted: Font: (Default) Times New Roman,
12 pt, Highlight
Formatted: Font: 12 pt, Not Bold, Highlight
Formatted: Font: 12 pt, Not Bold
18 
 
Table S5. Association of rs9357347 with cognition. 
Phenotype  N  beta  SE  p‐value  
Global cognitive decline  470  ‐0.007  0.007  0.320 
Global cognition at last visit  493  ‐0.058  0.071  0.418 
 
Measures of cognition that were available in the ROS/MAP cohort were tested for association 
with rs9357347 using linear regression under an additive model, including age-at-death, sex and 
APOE 4 dose as covariates. N = sample size. SE = standard error. Z scores of the cognitive 
scores were analyzed, thus these beta coefficients can be interpreted as changes in z-score 
associated with each copy of the minor allele. 
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Supplementary Figures 
Fig. S1. Spearman correlation plots for TREML1 and TREM2 brain expression levels 
measured by WG-DASL vs. RNAseq approaches. 
 
 (A) TREML1 and (B) TREM2 temporal cortex gene expression residuals (adjusted for 
covariates) are plotted for RNAseq vs. WG-DASL values. The Spearman correlation coefficient 
is shown above the scatter plot and the correlation p-value is shown inside the plot. The RNAseq 
and DASL residuals show a highly significant positive correlation. 
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Fig. S2. Box plots of rs9357347 genotype associations with TREML1 and TREM2 brain 
gene expression levels.  
 
Gene expression residuals obtained in R adjusted for covariates [APOE 4 dosage, age at death, 
diagnosis, sex, PCR plate, RIN, (RIN-RINmean)2] were plotted for each rs9357347 genotype. 
Each circle represents an individual gene expression residual; the horizontal line within the box 
is the median; the box represents the interquartile range (IQR); the whiskers represent the range 
of the data points within 1.5 × IQR below the 1st quartile and 1.5 × IQR above the 3rd quartile 
(anything outside of this range is called an outlier). The x-axis indicates the number of minor 
alleles. The minor (C) allele of rs9357347 is associated with increased brain expression of both 
TREML1 and TREM2. 
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Fig. S3. Regional association plot showing AD-risk and TREML1 eQTL p-values at the 
TREM locus. 
 
On this plot each variant is depicted as both, a circle denoting its IGAP stage 1 meta-analysis p-
value, and a diamond denoting its TREML1 eQTL p-value. All variants at the TREM locus that 
either achieved a p-value ≤ 0.0015 in the IGAP stage1 meta-analysis or that had a TREML1 p-
value < 0.05 in our eQTL analysis of temporal cortex gene expression measured by WG-DASL 
mircroarrays are shown, with p-values indicated by the scale on the left y-axis as –log10(p-value). 
The putative regulatory variant, rs9357347, is represented by the purple circle/diamond. The 
colors of all other circles and diamonds correspond to the colors on the r2 scale shown at the top 
right corner of the plot, and denote the LD of each variant with rs9357347. The values on the y-
axis on the right side of the plot correspond to the recombination rates across this region as 
shown by the blue line. Variants that have Regulome scores <3 are shown directly below the 
22 
 
plot. Gene locations across the targeted genomic region (TREM gene +/-100 kb: chr6:41016999-
41354457) are shown below the plot relative to the variant positions according to the February 
2009 human genome assembly (GRCh37hg19). The regional association plot was generated 
using LocusZoom (http://locuszoom.sph.umich.edu/locuszoom/). 
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Fig. S4. Regional association plot showing AD-risk and TREM2 eQTL p-values at the 
TREM locus. 
 
On this plot each variant is depicted as both, a circle that denotes its IGAP stage 1 meta-analysis 
p-value, and an “X” denoting its TREM2 eQTL p-value. All variants at the TREM locus that 
either achieved a p-value ≤ 0.0015 in the IGAP stage1 meta-analysis or that had a TREM2 p-
value < 0.05 in our eQTL analysis of temporal cortex gene expression measured by WG-DASL 
mircroarrays are shown, with p-values indicated by the scale on the left y-axis as –log10(p-value). 
The putative regulatory variant, rs9357347, is represented by the purple circle/X. The color of all 
other circles and Xs correspond to the colors on the r2 scale shown at the top right corner of the 
plot, and denote the LD of each variant with rs9357347. All other symbols are described in Fig. 
S3. 
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Fig. S5. Box plots of gene expression residuals for TREML1 and TREM2 in AD and nonAD 
subjects, for each of the three cohorts investigated. 
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A and B: Expression measure residuals for TREML1 (A) and TREM2 (B) in the Mayo WG-
DASL dataset, adjusted for rs9357347 minor allele dose, age-at-death, sex, APOE 4 dose, RIN, 
(RIN-RINmean)2 and PCR plate. TREML1 (C) and TREM2 (D) in the Mayo Clinic RNAseq 
dataset, adjusted for rs9357347 minor allele dose, age-at-death, sex, APOE 4 dose, RIN, (RIN-
RINmean)2 and flowcell. TREML1 (E) and TREM2 (F) in the ROS/MAP RNAseq dataset, 
adjusted for rs9357347 minor allele dose, age-at-death, sex, APOE 4 dose, RIN, (RIN-
RINmean)2. 
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Fig. S6. Bar charts of percentage of subjects with detectable gene expression for TREML1 
and TREM2 across groups of subjects defined by RIN value. 
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Subjects were binned according to RIN value and the proportion of subjects in each bin that met 
the detection threshold was calculated. A and B: Expression detection percentage for each RIN 
bin for TREML1 (A) and TREM2 (B) in the Mayo WG-DASL dataset. C and D:  Expression 
detection percentage for each RIN bin for TREML1 (A) and TREM2 (B) in the Mayo Clinic 
RNAseq dataset.  E and F:  Expression detection percentage for each RIN bin for TREML1 (A) 
and TREM2 (B) in the ROS/MAP RNASseq dataset. 
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    Percent Detection in Cerebellum  Percent Detection in Temporal Cortex 
Symbol  Probe ID  AD + non‐AD  AD  nonAD 
AD + non‐
AD  AD  Non‐AD 
TREM1  ILMN_1688231  0  0  0  0.25  0  0.51 
TREML1  ILMN_1690783  100  100  100  100  100  100 
TREM2  ILMN_1701248  40.91  43.59  37.29  98.25  99.5  96.95 
TREML2  ILMN_1740864  17.38  17.44  17.51  6.27  10.4  2.03 
TREML4  ILMN_2205322  6.15  4.62  7.91  2.26  2.97  1.52 
 
 
